Molecular determinants of Kaposi\u27s sarcoma-associated herpesvirus tumorigenicity by Kong, Haixia
Louisiana State University
LSU Digital Commons
LSU Master's Theses Graduate School
2008
Molecular determinants of Kaposi's sarcoma-
associated herpesvirus tumorigenicity
Haixia Kong
Louisiana State University and Agricultural and Mechanical College, haixia.kong@gmail.com
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Veterinary Pathology and Pathobiology Commons
This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU
Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact gradetd@lsu.edu.
Recommended Citation
Kong, Haixia, "Molecular determinants of Kaposi's sarcoma-associated herpesvirus tumorigenicity" (2008). LSU Master's Theses. 2933.
https://digitalcommons.lsu.edu/gradschool_theses/2933
  
MOLECULAR DETERMIATS OF KAPOSI’S SARCOMA-





Submitted to the Graduate Faculty of the 
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the 
requirements for the Degree of 







The Interdepartmental Program in 
Veterinary Medical Sciences through the 










DVM, Nanjing Agricultural University, 2004 
August, 2008 
 
- ii - 
ACKOWLEDGEMETS 
I certainly could not have accomplished my goals without the infinite encouragement of my 
family, who have provided endless support for me across the Pacific Ocean; I am eternally in 
their debt and can only offer the humble thanks of a grateful child.  My husband as well has been 
incredibly supportive, and I thank him for all of his patience and love. 
 I can only begin to thank my mentor Dr. Kousoulas.  He has been a strong teacher and 
unwaivering guide in my journey here.  I thank him for everything he has taught me, and the 
tremendous opportunities that he has created for me are invaluable.  I would also like to thank 
my graduate committee members, Dr. Nobuko Wakamatsu and Dr. Inder Sehgal for their 
invaluable recommendations and advice that have aided tremendously in my research.  In 
addition, I want to thank my graduate advisor Dr. James Miller for his support and help.  
 I would like to thank the members of the Kousoulas laboratory for their constant support 
and constructive criticism.  Especially, I thank Dr. Ramesh Subramanian, Arun Iyer, and Dr. 











- iii - 
TABLE OF COTETS 
ACKOWLEDGEMETS........................................................................................................ii 
LIST OF TABLES........................................................................................................................v  
LIST OF FIGURES......................................................................................................................vi  
ABSTRACT………………………………………………………………………………….…vii 
CHAPTER I: ITRODUCTIO.................................................................................................1 
STATEMET OF RESEARCH PROBLEMS AD HYPOTHESIS…………………......…1 
STATEMET OF RESEARCH OBJECTIVES………………………………………………2 
LITERATURE REVIEW……………………………………………………………………….3 
Historical Perspective of Kaposi’s Sarcoma-Associated Herpesvirus………..3 
     Clinical Significance of Kaposi’s Sarcoma-Associated Viruses ………….…...4 
            Kaposi’s Sarcoma (KS)................................................................................4 
Pleural Effusion Lymphoma (PEL) ............................................................9 
Multicentric Castleman’s Disease (MCD) ................................................10 
KSHV Genome Structure and Organization......................................................12 
The Core and Organization of the Viral Genome......................................13 
The Capsid.................................................................................................15 
The Tegument........................ ....................................................................17 
The Envelope ............................................................................................19 
  The Kaposi’s Sarcoma-Associated Herpesvirus Lifecycle...............................19 
Viral Attachment and Entry.......................................................................19 
Binding Receptors......................................................................................19 
Entry Receptors ………………………………………………………….20 
KSHV Latentcy..........................................................................................22 
   Viral Gene Transcription and Expression..................................................27 
Reactivation...............................................................................................30 
Regulation of Transcriptional Activation..................................................33 
Viral DNA Replication .............................................................................36 
KSHV Glycoproteins and Their Putative Functions..........................................39 
Glycoprotein B (gB) .................................................................................39 
KSHV K8.1………………………………………………………………43 
Glycoprotein H (gH) and Glycoprotein L (gL) .........................................44 
Glycoprotein M (gM) and Glycoprotein N (gN).......................................46 
Glycoprotein OX2 (vOX2) .......................................................................47 
REFERECES.............................................................................................................................48 
 
CHAPTER II: MOLECULAR DETERMIATS OF KSHV TUMORIGEICITY……83 
ITRODUCTIO…………………………………………………………….………………..83 
MATERIALS AD METHODS................................................................................................85 
Cells and Viruses Propagation……………………………………………….....85 
Antibodies………………………………………………………………………...86 
Vectors Construction……………………………………………………………86 
- iv - 
Codon Optimization………………………………………………..……………87 
Transient Transfection of BCBL-1 Cells……………………………………….88 
Tumor Formation………………………………………………………………..88 
In Vivo Imaging………………………………………………………………….89 
Viral DA Preparation…………………………………….…………..………..89 
Immunofluorescence Assay………………………………………………….….89 
BCBL-1 Cells Proliferation Rate Assay………………………………………..90 
Statistical Analysis………………………………………………………….……91 
RESULTS………………………………………………………………………….……………92 
Construction and Characteristics of Expression Plasmids……………………92 
Transient Expression of gB in 293 Cells………………………………………..92 
Transient Expression of gB in BCBL-1 Cells………………………………….94 
Quantification of KSHV by TaqMan PCR.................................................…....95 
Characteristics of PELs in ude Mice.........................................................…...98 
In vivo Imaging of PEL Tumors………………………………………………...98 
Proliferation of BCBL-1 cells In Vitro with Matrigel…………………………99 
PEL Tumor Growth……………………………………………………………100 
Pathobiological Examination of Tumors……………………………………...102 
Characterization of KSHV Infected PEL Tumors…………………………...103 
DISCUSSIO………………………………………………………………………………….105 
REFERECES………………………………………………………………………………...109 














- v - 
LIST OF TABLES 























- vi - 
LIST OF FIGURES 
Figure 1.1: KSHV Fusion and Entry……………………………………………………….…….22 
Figure 1.2: KSHV Gene Map……………………………………………………………………32 
Figure 2.1: Small Interfering RNAs (siRNAs) Selectively Block Expression of Genes………...93 
Figure 2.2: Strategy Used to Construct the Codon-Optimized KSHV gB………………………93 
Figure 2.3: siRNAs 18 and siRNAs 22 Specifically Inhibit KSHV gB Expression in 293 
Cells……………………………………………………………………………………………...94  
Figure 2.4: siRNAs 18 and siRNAs 22 Specifically Inhibit KSHV gB Expression in BCBL-1  
Cells……………………………………………………………………………………………...96  
Figure 2.5: Reduced KSHV Genomes in Supernatants from BCBL-1 Cells Transfected with  
siRNAs Determined by Quantitative Real-time PCR……………………………………………97 
Figure 2.6: A Representative Subcutaneous Mass before and after Dissection…………………98  
Figure 2.7: X-ray and Fluorescent Image of Nude Mouse ……………………………………..99 
Figure 2.8: In Vitro GFP+ BCBL-1 Cells Proliferation Rate with Matrigel…………………...100 
Figure 2.9: Effect of Transfected BCBL-1 Cells in Nude Mice………………………………..101  
Figure 2.10: Subcutaneous Masses Stained with Hematoxylin and Eosin (H&E)……………..103  






- vii - 
ABSTRACT 
A conditional silencing system using anti-gB siRNAs was devised to investigate the structure 
and function of the KSHV gB. Transient co-transfection of plasmids constitutively expressing 
gB and anti-gB siRNAs in 293 cells substantially inhibited gB mRNA levels and protein 
production. Similarly, transient expression of siRNAs into the basal cavity-based lymphoma 
cells (BCBL-1) caused substantial reduction of gB transcription and protein synthesis. TaqMan 
real-time PCR and infectivity assays showed that gB was essential for virion egress and 
infectivity. Transfection of a codon-optimized gB not recognized by the anti-gB siRNAs, 
efficiently rescued virion egress and infectivity in BCBL-1 cells in the presence of siRNAs 
inhibiting wild-type gB expression. Virion egress experiments with truncated gBs revealed that 
removal of the entire predicted cytoplasmic domain of gB increased virion egress suggesting the 
presence of a egress-regulation domain located proximal to the intramembrane sequence within 
the cytoplasmic domain of gB. All supernatant virions were infectious on 293 cells indicating 
that the carboxyl terminus of gB is not essential for either virion egress or virus infectivity. To 
investigate the potential role of gB in tumorigenesis, BCBL-1 cells transiently transfected with 
anti-gB siRNAs and codon optimized gB were mixed with Matrigel and injected subcutaneously 
in nude mice.  Direct measurement of tumors revealed that BCBL-1 cells transfected with anti-
gB siRNAs produced tumors significantly smaller than mock-transfected BCBL-1 cells. Co-
transfection of codon optimized gB appeared to abrogate the inhibition of tumor formation by 
siRNAs. These results show that gB is important for infectivity, virion egress and pleural 
effusion lymphoma (PEL) formation in mice. Current work focuses on the use of a lentiviral 
expression system to generate BCBL-1 cells that constitutively express anti-gB siRNAs to 
improve inhibition of endogenous gB expression. 
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CHAPTER I 
ITRODUCTIO 
STATEMET OF RESEARCH PROBLEMS AD HYPOTHESIS 
Kaposi’s sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV-8) is a 
member of the gamma-2-herpesvirus family (genus Rhadinovirus).  In 1994, the virus was first 
discovered in Kaposi’s sarcoma (KS) tumors of AIDS patients.  KSHV is associated with 
Kaposi’s sarcoma, primary effusion lymphoma (PEL) or body cavity-based lymphoma (BCBL), 
and multicentric Castleman’s disease.  To date, KSHV has shown to be required for disease 
manifestation, yet certain basic mechanisms by which KSHV promotes oncogenesis and 
tumorigenicity have not been clearly understood, including the roles of  KSHV glycoproteins in 
PEL. 
PEL cell lines represent the most consistent model for the study of KSHV.  Most PEL 
cells are latently infected, and only a very small percentage of infected cells undergo random 
lytic infection.  KSHV encodes a number of glycoproteins, some of which are conserved within 
the Herpesviridae Family. Glycoprotein B mediates the initial virion binding to 
glycosaminoglycans, e.g., adherent target cell surface heparan sulfate molecules (Akula et al., 
2001b).  KSHV gB also binds to α5β3 integrin through the RGD (Arg-Gly-Asp) motif and its 
associated signaling pathways that are important for KSHV entry into target cells (Akula et al., 
2001a; Birkmann et al., 2001; Garrigues et al., 2008; Wang et al., 2001a).  Previous studies from 
our laboratory showed that the carboxyl terminus of herpes simplex virus type 1 (HSV-1) gB is 
associated with virus-induced and virus-free cell fusion (Baghian et al., 1993; Foster et al., 
2001).  Truncation of the carboxyl terminus of pseudorabies virus gB has shown that 
internalization of gB is not required for gB incorporation into virions nor for its function in either 
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entry or cell-to-cell spread (Nixdorf et al., 2000; Pertel et al., 2002).  It has been reported that gB 
activates the vascular endothelial growth factor receptor 3 (VEGFR-3) indicating the importance 
of KSHV in PEL pathogenesis (Zhang et al., 2005). 
The overall experimental approach focused on the role of KSHV gB in viral egress and 
tumorigenicity.  Two gB carboxyl terminal truncations having 25 and 56 amino acids deleted 
were generated. In addition, two other gB deletions lacked the entire cytoplasmic domain of gB 
and the cytoplasmic domain with part of the carboxyl terminal-most intramembrane sequence. 
These gB truncations were tested for their ability to rescue siRNA-inhibited gB synthesis with 
regard to virion egress and infectivity. It was found that the carboxyl terminus of gB was not 
important for either virion infectivity or egress.  To investigate the role of gB in tumorigenicity, 
we injected nude mice subcutaneously with BCBL-1 cells transfected with anti-gB siRNA, 
codon-optimized gB and p3xFlag in the presence of Matrigel.  BCBL-1 cells transfected with 
anti-gB siRNA in nude mice produced significantly smaller tumors than the mice transfected 
with codon-optimized gB and p3xFlag vector.  These results provide new insights into the roles 
of KSHV gB in virion egress, infectivity and tumorigenicity. 
STATEMET OF RESEARCH OBJECTIVES 
The overall goal of this research is to gain a better understanding of the role that major viral 
glycoproteins play in the KSHV lifecycle and pathogenesis.  The specific objectives are:   
1.)  Evaluate the role of gB carboxyl terminus domains in infectivity and viral egress from 
infected cells by generating several site carboxyl terminal truncations of gB. 
 2.)  Investigate the role of gB in tumorigenesis. 
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LITERATURE REVIEW 
Historical Perspective of Kaposi’s Sarcoma-Associated Herpesvirus 
Kaposi’s sarcoma was first described by Moritz Kaposi in 1872. It has been known as a rare 
disorder of older men usually of Eastern European, Mediterranean, and/or Jewish origin. 
Subsequently, three additional forms of Kaposi’s sarcoma have also been classified: African-
endemic, iatrogenic (in organ and tissue transplant recipients receiving immunosuppressive 
therapy) and AIDS-KS or (Aluigi et al., 1996; Ambroziak, 1995)  Foreman et al., 1997a; (Gao et 
al., 1996a; Kedes et al., 1996; Lennette, Blackbourn, and Levy, 1996; Miller et al., 1996; 
Parravicini et al., 1997b; Qunibi et al., 1998; Regamey et al., 1998; Schalling et al., 1995; 
Simpson et al., 1996).   It is now established that KSHV infection of the host is common among 
all four epidemiological forms despite their numerous clinical differences.   
 In 1994, an innovative technique of representational difference analysis (RDA) was used 
to identify unique herpesvirus-like DNA sequences.  This study led to the discovery of a new 
human herpesvirus (named Kaposi’s Sarcoma-associated Herpesvirus or human herpesvirus 8) 
from patients infected with both AIDS and KS but not from patients with AIDS who are without 
KS (Chang et al., 1994).  In 1995, primary effusion lymphoma was first described in AIDS 
patients.  Since then, Kaposi’s sarcoma-associated herpesvirus (KSHV) has also been associated 
with multicentric Castleman’s disease (MCD), primary pulmonary hypertension and 
solid/extracavitary lymphomas with similar morphological and immunophenotypical 
characteristics to those of PEL.  The PEL cells are able to support continuous KSHV infection 
and conditional productive virus replication leading to the study of KSHV.  
 Herpesviruses are double-stranded DNA viruses and highly disseminated in nature.  
KSHV and Epstein Barr virus (EBV) are human gamma-herpesviruses known for their 
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involvement in cancers and cellular proliferation.  KSHV can infect lymphocytes, endothelial 
cells, keratinocytes, human foreskin fibroblast, Vero, 293, HeLa cells, etc.  KSHV has aroused 
substantial scientific interest as a new human DNA tumor virus. Sequence analysis shows that 
KSHV genome encodes many cellular homologous genes involved in cell cycle regulation, cell 
proliferation, apoptosis, and immune modulation.  
Clinical Significance of Kaposi’s Sarcoma-Associated Viruses 
Kaposi’s Sarcoma (KS) 
Kaposi’s sarcoma (KS) is the most common AIDS-defining malignancy characterized by 
multifocal tumor lesions, neo-angiogenesis, proliferation of spindle cells, and infiltration with 
inflammatory cells and erythrocytes.  KS tumors are most commonly found in the dermis but 
also occur in viscera including liver, lungs and intestines (Hengge et al., 2002).  Visceral 
dissemination results in organ failure and eventual death.  The majority of the cells are latently 
infected with a small subpopulation of lytically infected cells.  Both latent and lytic infections 
make important contributions to KS pathogenesis.   
 Overall, KSHV infects approximately 40% of gay men and over 60% of Sub-Saharan 
Africans in many countries.  KSHV is necessary for all clinical forms of Kaposi’s sarcoma, but it 
is not sufficient to cause KS.  It is now believed that AIDS is very important in KS pathogenesis 
by causing immunosuppression.  Therefore, KS is now the dominant malignancy in many 
African countries with a high prevalence of AIDS (Dedicoat and Newton, 2003).  
 KSHV seroconversion could be used to predict the development of the disease (Cesarman 
et al., 1996b; Gao et al., 1996a; Kedes et al., 1996; Martin et al., 1998; Renwick et al., 1998).  
These investigations reveal a substantial role for cofactors in KS pathogenesis (Dourmishev et 
al., 2003).  Recent studies suggest that cigarette smoking decreases KSHV risk while drinking is 
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associated with a higher risk of AIDS-associated KS (Hoover et al., 1993; Mbulaiteye et al., 
2006; Nawar et al., 2005). 
Classical KS primarily occurs in elderly men of Eastern European, Mediterranean, or 
Jewish descent (Ablashi et al., 2002; Dourmishev et al., 2003; Moore and Chang, 2003).  In the 
late 1800s, Moritz Kaposi first described the clinical condition of “classical” KS as multifocal 
pigmented sarcomas (Kaposi, 1872).  Classical KS tumors confined themselves to the lower 
extremities for ten or more years with a benign course (Hengge et al., 2002).  The first signs of 
KS are often the bluish-red macules or papules on the distal lower extremities resulting in 
multifocal patches and nodules.  Those initial patients died of KS, and the clinical presentation of 
the disease grossly resembles what we currently find in KS patients (Knipe and Philadelphia, 
2001).  Unlike AIDS-associated KS, HIV-1 co-infection is rare but has been strongly suggested 
as a cofactor (Vitale et al., 2001).  Extensive epidemiological studies demonstrated a high 
prevalence of KSHV in the Mediterranean contrasted with non-Mediterranean countries.  Both 
sexual and nonsexual modes are probably the two transmission routes of KSHV in classic KS. 
Saliva has also been suggested as a predominant route in classic KS (Cattani et al., 1999). 
AIDS-associated or Epidemic AIDS KS is the most common AIDS-associated neoplasm 
in homosexual and bisexual men (Feigal, Cheson, and Nelson, 1997).  The epidemic AIDS KS, 
much more so than in the other epidemiologic forms, is an extremely aggressive mucosal 
progression in the AIDS-infected homosexual and bisexual population (Schwartz, 1996).  The 
prevalence of epidemic KS is approximately 20-fold higher in homosexual AIDS patients than in 
other HIV infected patients (Goedert, 2000).  However, the incidence of AIDS-related KS has 
been decreased due to the highly active antiretroviral therapy (HAART) available in western 
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countries (Cattelan et al., 2001). The HIV-1 specific protease inhibitors (PIs) are anti-angiogenic 
and can inhibit the development of angiogenic lesions.   
 This disease is most commonly found multifocally and frequently on the upper body, 
head and neck (Hengge et al., 2002).  It quickly evolves to tumors from local lesions and in 
visceral dissemination resulting in organ dysfunction and high mortality rates.   Similar to classic 
KS, the relative seroprevalence of KSHV is consistent with the KS incidence in HIV-infected 
populations.  It is now well established that a direct correlation exists between HIV-1-infected 
AIDS pathogenesis and KS progression (Borkovic, 1981; Gottlieb, 1981; Hymes, 1981).  The 
co-infection of KSHV and AIDS contributes to KSHV pathogenesis at multiple levels, including 
immunosuppression, enhancement of KSHV infection and viral DNA replication, as well as 
direct effects on KSHV gene expression (Dourmishev et al., 2003).   
Recent studies have suggested that sexual transmission of KSHV is the most significant 
risk factor for HIV-infected populations (Martin et al., 1998).   Evidence from a cohort study of 
seropositivity and seroconversion demonstrated that orogenital rather than anogenital sex is a 
stronger risk factor for KSHV infection (Dukers et al., 2000).  The primary mode of KSHV 
transmission has not be completely understood, but recent studies have postulated that KSHV 
transmission via the oral route may also occur among healthy immunocompetent individuals 
(Cook et al., 2002a; Cook et al., 2002b; Duus and Grose, 2007; Duus et al., 2004).  A 
retrospective study, analyzing the prevalence of KSHV infection among homosexual men at the 
beginning and during the AIDS epidemic, showed that unprotected oral sex posed the highest 
behavioral risk factor (Osmond et al., 2002).  KSHV has also been detected in the saliva of 
seropositive individuals (Blackbourn et al., 2000; Koelle et al., 1997; Pauk et al., 2000; Vieira et 
al., 1997), but it is extremely difficult to detect KSHV in semen, with very low reproducibility.  
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In addition, many other routes of transmission have been studied for KSHV and HIV 
pathogenesis.  A very recent study has inplicated that salivary and possible nosocomial HHV-8 
transmission may exist in rural Egypt (Mbulaiteye et al., 2008).  
Endemic (African) KS has been found for many decades in Africa, particularly the 
equatorial region, prior to the worldwide spread of HIV (Oettle, 1962).  The highest prevalence 
of African KS patients have been observed in Zaire, Uganda, and Tanzania (Ablashi et al., 2002).  
Before the emergence of HIV, African KS primarily affected children of approximately three 
years of age and young men around age thirty-five (Wabinga, 1993).   
 Microparticles of silica dust in volcanic soils have been suggested as environmental 
contributors in children infected with African KS (Ziegler, Simonart, and Snoeck, 2001).  
Mircroparticles penetrate the skin of the barefoot and then migrate into the lymphatics, leading to 
inflammation and lymphedema.  Aluminosilicates from animal models associated with the direct 
intralymphatic injection of fine silica particles cause cytotoxic effects on macrophages, leading 
to subsequent fibrosis within lympho-vessels (Fyfe et al., 1985).  Thus, children who walk 
barefoot could risk the penetration of silica microparticles into their feet, likely resulting in 
localized immune suppression. This localized immune suppression would provide the proper 
environment for the development of African KS in KSHV-infected individuals (Ablashi et al., 
2002).  However, clinical epidemiologic studies of KS in Africa suggest that African KS is most 
likely dependent on the spread of AIDS, which in turn facilitates the prevalence of endemic KS.   
 Clinically, KS in Africa is more frequently found in children and women than anywhere 
else worldwide (Kasolo, Mpabalwani, and Gompels, 1997; Wawer et al., 2001; Ziegler and 
Katongole-Mbidde, 1996).  African KS is typically more aggressive than classic KS but similar 
to the progression of AIDS-related KS.  The endemic KS in Africa with high prevalence in 
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childhood indicates that KSHV transmission patterns are primarily nonsexual and horizontal, 
with a few vertical instances.  Other evidence also points out that population-delimited routes 
occur in Africa (Enbom, Linde, and Evengard, 2000; Enbom et al., 2000).   
Iatrogenic (transplant) KS with a prevalence of 0.5-5% depending on the patient's country 
of origin and the type of organ received is becoming a growing concern for solid-organ 
transplant patients, (Tan and Goh, 2006).  It is now well established that KSHV is 
epidemiologically associated with KS in post-transplant patients, predominantly after renal 
transplantation (Luppi, Barozzi, and Torelli, 2003).  Unlike lymphomas or different epithelial 
malignancies, iatrogenic KS represents an earlier manifestation of post-transplantation 
malignancy in recipients (Penn et al., 1993).  KSHV infection in transplant KS patients 
progresses either chronically or rapidly.  In general, transplant patients with KS present the 
manifestation of visceral dissemination of KS with occasional skin lesions (Singh, 2000).  
The incidence of iatrogenic KS is 500 times greater than in the general population and its 
occurrence is introduced by immunosuppressive therapy.  However, the remission of KS has 
been observed in all variants of KS when immunosuppression is removed.   More than fifty 
percent of transplant associated KS patients have had tissue rejection when immunosuppression 
is reduced or withdrawn (Singh et al., 2000).  Extreme ethnogeographic associations have been 
shown in iatrogenic KS (Penn, 1993).  The route of transmission among iatrogenic KS patients 
has not been fully understood.  However, three separate routes have been suggested: donor 
organ, blood transfusions, and caregivers (Jenkins, Hoffman, and Liegey-Dougall, 2002).  Two 
possible mechanisms of post-transplant KS have also been suggested: KSHV reactivation in 
patients who were infected before the graft, and KSHV primary infection through infected organ-
donor tissues.  It has been reported that KSHV reactivation of latent viral infection plays a 
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greater role in iatrogenic KS in areas of endemic KS, in contrast to nonendemic KS areas, where 
it is believed that KSHV primary infection is the major cause of post-transplantation KS 
(Rabkin, Shepherd, and Wade, 1999).  Many studies have suggested that KSHV primary 
infection is significantly higher than previously expected (Andreoni et al., 2001; Cattani et al., 
2001; Emond et al., 2002; Farge et al., 1999; Kapelushnik et al., 2001; Luppi et al., 2000a; Luppi 
et al., 2000b; Munoz et al., 2002; Sarid, Klepfish, and Schattner, 2002).  To date, there is no 
precise estimate of KSHV seroprevalence in organ donors, and recipients in different countries.  
Thus, it is still debated whether or not to screen donors/recipients for KSHV due to the potential 
risk for KSHV-related disease development.  
Pleural Effusion Lymphoma (PEL) 
Pleural effusion lymphomas (PELs) or body cavity-based lymphomas (BCBL) were first 
described in AIDS patients (Cesarman et al., 1995).  Compared to KS, PELs manifest the more 
common neoplasm characterized by irregular cellular expansion of transformed cells (Knipe et 
al., 2001).  PELs are very rare; they are predominately but not exclusively found in HIV infected 
patients with extremely poor prognosis (Kaplan et al., 1997; Levine et al., 1991).  PEL exhibits 
malignant effusions in the peritoneal, pericardial, pleural, or abdominal cavity, typically without 
an identifiable tumor mass (Aoki, Jones, and Tosato, 2000; Leao et al., 2002).  In rare cases, the 
solid tumor masses of PELs were also found outside the body cavities (Aoki and Tosato, 2003).  
 PELs are monoclonal non-Hodgkin’s B cell lymphomas derived from late-stage 
differentiated pre- and post-germinal center B cells. Therefore, any stage of B cell maturation 
can be found in PELs (Carbone et al., 1998; Matolcsy, 1999).  In addition, another study has 
shown that KSHV was also detected in circulating B cells (Blackbourn and Levy, 1997).  PEL 
tumor cells lack B cell specific surface markers and are commonly dually infected with Epstein-
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Barr virus (EBV), which also transforms cells and lead to lymphopreliferative disorders in 
infected patients (Ablashi et al., 2002).    
 PEL cell lines derived from PEL have been demonstrated to be the best source for 
infectious virus production (Moore and Chang, 2003).  Unlike KS tumor explants, PEL cell lines 
stably maintain viral episomes at high copy numbers (50–150 copies per cell).  Typically, the 
majority of PEL cells are latently infected by KSHV; a small percentage (<3%) of cell 
populations spontaneously undergo lytic reactivation (Renne et al., 1996b).  Lytically infected 
cells can be induced by a phorbol ester, tetradecanoyl-13-myristate acid or TPA (Renne et al., 
1996a; Renne et al., 1996b; Sarid et al., 1998; Zhong et al., 1996). 
Multicentric Castleman’s Disease (MCD) 
Multicentric Castleman's disease (MCD), also known as multicentric angiofollicular lymphoid 
hyperplasia, is a rare lymphoproliferative disorder.  MCD exhibits a systemic proliferation, 
including lymphadenopathy and splenomegaly, in part due to raised serum concentration of 
interleukin 6 (Mikala et al., 1999).  Clinically, MCD is classified into two forms: single 
mediastinal angiofollicular lymph-node hyperplasia localized Castleman’s disease and multifocal 
or multicentric Castleman’s disease with multisystem involvement accompanied by generalized 
lymphadenopathy.  Similar to KS, MCD is also characterized by vascular proliferation in the 
germinal centers (Ablashi et al., 2002).  Morphologically, the cells containing KSHV genomes in 
multicentric Castleman’s disease are similar to immunoblasts, with prominent central or 
marginal nuclei (Judde et al., 2000; Parravicini et al., 2000).  
 MCD has been reported in close association with KSHV in both HIV-seropositive and 
HIV-seronegative patients. The precise incidence of MCD is unknown; although, MCD is more 
common in HIV-positive than HIV-negative individuals.  KSHV has been found mostly (greater 
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than 90%) in HIV-related MCD in AIDS patients (Aoki and Tosato, 2003; Leao et al., 2002).  
This feature of MCD strongly suggests an important role of KSHV in the pathogenesis of MCD, 
particularly in AIDS patients (Grandadam et al., 1997).  Furthermore, in AIDS related MCD, an 
increased KSHV viral load is correlated with the exacerbation of MCD symptoms even though 
no manifest MCD foci were found within the lymph nodes of the infected patient (Parravicini et 
al., 1997a).  In HIV-negative healthy individuals, fifty percent of all individuals with MCD are 
infected with KSHV.  However, unlike KS and PEL, not all Castleman’s disease has been found 
to contain KSHV genomes indicating more than one etiologic factor contributing to the disease 
(Moore and Chang, 2003).  In patients co-infected with HIV and KSHV, MCD presents itself in 
a significantly more aggressive form.  The prognosis of MCD in HIV-positive patients generally 
remains poor with a median survival of 48 months from diagnosis and a 15-fold increased risk of 
non-Hodgkin's lymphoma (Oksenhendler et al., 2000; Parravicini et al., 1997a; Zietz et al., 
1999).  
 MCD is a polyclonal tumor. In MCD, the majority of the cell mass is composed of 
uninfected lymphocytes which are recruited to the site of infection by cytokines released from 
KSHV infected B cells (Dupin et al., 1999; Katano et al., 2000; Parravicini et al., 1997a).  In 
contrast to PELs in which the majority cells are dually infected with KSHV and EBV, MCD 
usually is negative for EBV (Aoki, Jones, and Tosato, 2000; Little et al., 2001).  There is higher 
number of lytic KSHV genomes in MCD than in PEL implying different KSHV pathogenetic 
mechanisms between MCD PEL.  The different mechanisms of MCD and PEL may be due to 
different cellular and viral gene expression profiles in both of these lymphoproliferative 
disorders (Rivas et al., 2001; Staskus et al., 1999; Teruya-Feldstein et al., 1998). 
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KSHV Genome Structure and Organization 
Many studies of KSHV viral structure have shown that KSHV shares similar structure features 
with other members of the Herpesviridae family.  Typically, the observed size of KSHV virion 
particles is approximately 100-150nm (Renne et al., 1996b).  Like other herpesviruses, KSHV is 
comprised of four structural elements: 1.) a large linear double-stranded DNA in a cylindrical 
core; 2.) an icosahedral capsid composed of 162 hexagonal capsomeres; 3.) an amorphous 
tegument surrounding the capsid, and 4.) a lipid bilayer envelope derived from the host cell 
(Knipe et al., 2001). 
 The KSHV genome was determined by sequencing of viral DNA isolated from both a 
PEL cell line and biopsy specimens of KS.  Virion DNA released from BCBL-1 cells treated 
with phorbol ester (12-O-tetradacanoyl-13-acetate; TPA) revealed that the KSHV genome is 
comprised of approximately 165kb to 170kb (Renne et al., 1996a; Zhong et al., 1996).  
Compared to the prototypical herpesvirus HSV-1 genome which is 135 kb, the KSHV genome 
size is a bit larger.  However, the KSHV genome is substantially smaller in size than the viral 
genome of the human cytomegalovirus (HCMV).  Although numerous published results have 
thoroughly investigated molecular aspects of the KSHV lifecycle further, virion structure and 
morphology is still unclear due to the difficulty ofcultivating KSHV in either tissue culture or 
animal systems.  Negative stained images of thin sections revealed that KSHV and HCMV 
capsids are similar.  The KSHV nucleocapsid was observed to be approximately 120-150nm, 
while HCMV nucleocapsid was shown to be 150-200nm (Sarid et al., 1997).  It has been shown 
that the capsid size and structure are consistent with other members of the herpesvirus family by 
using electron cryomicroscopy (Trus et al., 2001; Wu et al., 2000). 
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The Core and Organization of the Viral Genome 
Like all other herpesviruses, the innermost core of the KSHV particle consists of wound viral 
DNA genome (Knipe et al., 2001).  Herpesviruses possess a linear double-stranded DNA 
genome with a size range from 120kb to 250kb. DNA purified from intact virions showed that 
the KSHV genome is approximately 165kb to 170kb by using pulse-field gel electrophoresis 
(Renne et al., 1996a).  Nucleotide sequence data suggests that KSHV is a member of the 
gammaherpesvirus subfamily, genus Rhadinovirus (gamma-2 herpesvirus), which also includes 
the new world monkey virus, herpesvirus saimiri (saimiriine herpesvirus 2, HVS).  KSHV is the 
first member of this genus known to infect humans (Moore et al., 1996b).   
 The linear double stranded genome consists of a continuous 140.5kb central region 
composed of low-GC DNA [also known as L DNA or long unique region (LUR)], which has 
53.5% G+C content (Moore et al., 1996b; Neipel, Albrecht, and Fleckenstein, 1997; Russo et al., 
1996).  The LUR is flanked by the 20-35kb multirepetitive terminal region containing high GC 
DNA, which has 84.5% G+C content terminal repeat units (TR) (Neipel, Albrecht, and 
Fleckenstein, 1997).   
Approximately 90 genes have been identified in the KSHV’s long unique region, which 
resembles the genetic organization of herpesvirus saimiri (HVS) (Moore et al., 1996; Neipel, 
Albrecht, and Fleckenstein, 1997).  About 70 conserved genes arranged co-linearly are found in 
both KSHV and HVS with small intermittent regions contain unique genes of each virus.  
Corresponding to the previous nomenclature of genes for HVS, all conserved genes have been 
designated the prefix “ORF” and numbered consecutively from left to right across the viral 
genome, while the KSHV unique genes within the intermittent regions have been denoted K1 to 
K15 (Russo et al., 1996).  The genetic organization was shown to be highly conserved among 
- 14 - 
other nonhuman members of the genus rhadinovirus, such as the rhesus rhadinovirus and murine 
gammaherpesvirus 68.  The conserved genes among the rhadinovirus genus function 
metabolically or catalytically in both virion structure and viral DNA replication, including 
glycoprotein B (ORF8), DNA polymerase (ORF9), thymidine kinase (ORF21),  glycoprotein H 
(ORF22), DNA helicase-primase complex (ORF40, ORF41 and ORF44), splicing factor 
(ORF57), polymerase processivity factor (ORF59), p33 (ORF69), thymidylate synthase (ORF70) 
, serine/threonine protein kinase (ORF36) (McGeoch and Davison, 1999; Moore et al., 1996b; 
Neipel, Albrecht, and Fleckenstein, 1997; Park et al., 2007; Russo et al., 1996; Santarelli et al., 
2008).  
 KSHV shares both structural and biological features with the Epstein-Barr virus (EBV), 
the only other human gammaherpesvirus causing human tumors.  The two viruses are oncogenic 
tumor viruses, although KSHV contains none of the EBV-like unique latency genes in cell 
immortalization and transformation (Knipe et al., 2001; Russo et al., 1996).  A clear genetic 
correspondence was found between KSHV and EBV even though no homologies of latency 
genes were shown between KSHV and EBV (Moore and Chang, 2001). Both EBV and KSHV 
utilize B lymphocytes as reservoirs during latency and establish persistent infection in a similar 
B cell environment.  However, a certain set of cellular genes was induced by EBV proteins, and 
this set of human cDNAs was modified by KSHV that are captured and incorporated themselves 
into cellular genome (Knipe et al., 2001; Neipel, Albrecht, and Fleckenstein, 1997). Possible 
functional cross-complementation between members of the gammaherpesvirus subfamily has 
been suggested by the study of KSHV p33 that shares many similarities with its EBV BELF2 
(Santarelli et al., 2008).  
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The Capsid 
Similar to other herpesviruses, the KSHV virion has a multilayered architecture, with a double-
stranded DNA genome enclosed within an inner icosahedral capsid, a thick middle tegument 
compartment containing proteineases, and a lipid bilayer envelope embedded with glycoproteins 
(Steven, 1997).  The capsids are first formed after the initial KSHV replication in the nucleus and 
mature.  The capsids contain linear KSHV genome.  Only newly synthesized virions are 
packaged into the capsids (Knipe et al., 2001; Renne et al., 1996b).  Similar to encapsidated 
HSV-1 DNA, encapsidated KSHV DNA is present within the capsid as a single linear copy 
encoding the entire viral genome (Booy et al., 1991).  Unlike EBV, the KSHV genome is a large 
closed circular episome during latency, and the viral genome linearizes during virion packaging 
and replication (Decker et al., 1996).  The mechanism by which this packaging occurs has not 
been fully understood although the linear KSHV genome possibly enters into the capsid through 
a unique portal vertex (Cardone et al., 2007; Chang et al., 2007; Deng et al., 2007; Deng et al., 
2008; Newcomb et al., 2001; Trus et al., 2004).  Genetic and biochemical studies have suggested 
a bacteriophage-like, DNA-packaging/ejection portal complex, located at only 1 of the 12 
vertices of the capsid of herpesviruses, which has been demonstrated recently by cryo-electron 
tomography (cryoET) studies of native KSHV capsids (Nealon et al., 2001).  However, the exact 
arrangement and orientation of the portal complex remains unclear.  
 The nuclei of infected cells provide a source for biochemical analyses of HSV-1 and 
HCMV capsid structures (Homa and Brown, 1997); however, it is well recognized that isolating 
enough amounts of stable capsids in cell culture from both EBV and KSHV for structural studies 
is extremely difficult.  Lytic replication induced by chemical treatments in infected cells offers a 
stable source of KSHV capsids (Dolyniuk, Pritchett, and Kieff, 1976; Nealon et al., 2001; Wu et 
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al., 2000). The establishment of a stable source of KSHV capsids has allowed further 
determination of the proteins and the molecular ratios of the proteins involved in the composition 
and structure of the capsid (Nealon et al., 2001; Trus et al., 2001; Wu et al., 2000).  
 Since the 1970s, much biochemical evidence, visualized via electron microscopy and 
separated by density gradient sedimentation, have demonstrated that herpesviruses form in 
distinctive capsids during assembly in the host nucleus. The three major capsids were named A 
capsids, B capsids and C capsids according to the order of their positions on a density gradient.  
Later protein analysis and negative stain electron microscopy revealed that the capsid shell is a 
nearly identical icosahedral shell among three classes, and the classes are only differentiated by 
their inner contents.  A capsids are complete void of DNA or any detectable internal structure 
with a total mass of 200MDa.  B capsids contain an inner array of scaffolding protein from 
ORF17.5 (Nealon et al., 2001) with a total mass of 230 MDa.  C capsids are filled with the 
packed KSHV double-stranded DNA genome only but no scaffolding protein, which was present 
in the B capsids with a total mass of 300 MDa.  Biochemical and mass spectrometry studies 
showed that the A, B, and C capsid shells are composed of four viral proteins, including the 
ORF25/MCP (major capsid protein), ORF65/SCIP (small capsomer interacting protein), 
ORF62/TRI-1 (triplex monomer protein) and ORF26/TRI-2 (triplex dimer protein) (O'Connor 
and Kedes, 2006).  The smallest capsid proteins (SCPs) encoded by ORF65 gene have been 
found to localize at the outermost regions of the capsid. The localization of SCP suggests that 
SCP may be important in mediating capsid interactions with the tegument and cytoskeletal 
proteins during infection (Lo et al., 2003).  
Herpesvirus capsids consist of 150 hexameric and 12 pentameric capsomers formed 
exclusively from the KSHV-ORF25 product/MCP (the major capsid protein). The majority of 
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the capsid’s mass can be attributed to MCP, which is highly conserved throughout the 
herpesvirus family (Homa and Brown, 1997). The capsomers are linked together via hetero-
triplexes, which protrude from the capsid floor in between the capsomer structures (Trus et al., 
2001; Wu et al., 2000).  In KSHV, the heterotriplexes consist of two molecules of ORF26/TRI-2 
and one molecule of ORF62/TRI-1 (Nealon et al., 2001). Type C capsids are the only type of 
capsid isolated by deenveloping intact virions; furthermore, type C capsids are (about 10-15% of 
total capsids produced) produced the least from induced BCBL-1 cells (Gibson and Roizman, 
1972; Schrag et al., 1989).  The small percentage of type C capsids produced from BCBL-1 cells 
may provide an explanation for the low infectivity of KSHV in experiments using this cell line as 
a source of virus stock (Nealon et al., 2001).  Cryo-electron Tomography (cryoET) and three-
dimensional reconstruction techniques have been powerful tools in studying the structure of 
KSHV capsids.  KSHV capsids directly visualized by cryoET reveal a heterogeneous collection 
of similar but non-identical particles containing different amounts and configurations of SCAF, 
while neither A nor C-capsids showed structural variation (Deng et al., 2008). The highly 
variable SCAF may represent the existence of different intermediates during the KSHV capsid 
assembly and maturation.  
The Tegument 
The tegument of herpesviruses is a proteinaceous region contained between the outer surface of 
the capsid and the underface of the virion envelope.  The tegument is various in both size and 
composition (Roizman, 1974).  The tegument can be distributed asymmetrically and 
symmetrically. There is less tegument that are more symmetrically arranged in perinuclear 
virions than in virions in cytoplasmic vesicles that contain tegument distributed more 
asymmetrically (Falke, Siegert, and Vogell, 1959).  
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The studies of the structure and function of the herpesvirus tegument, particularly about 
the KSHV tegument, have provided limited information.  Tegument proteins play important roles 
in various aspects of the virus life cycle, the early events of infection and virion egress.  Certain 
herpesvirus tegument proteins have been shown to regulate the viral lifecycle, penetration of the 
virus into cells and viral replication (Knipe et al., 2001).  
KSHV ORF45 has been found in the tegument area of virions and plays a critical role in 
the KSHV lytic replication cycle (Zhu and Yuan, 2003).  It is an immediate-early protein, highly 
phosphorylated. OFR45 is expressed immediately after the virus enters the lytic cycle. Its 
expression level increases as lytic viruses replicate and remain at a high amount through the late 
stage (Zhu et al., 2005; Zhu, Cusano, and Yuan, 1999; Zhu and Yuan, 2003).  Previously, ORF45 
protein has been shown to interact with cellular IRF-7 (interferon regulatory factor 7) and 
suppress its phosphorylation and nuclear accumulation, indicating a role of ORF45 in inhibiting 
the host anti-viral response (Zhu et al., 2002).  IRF-7 regulates the type I Interferons (IFNs) and 
induction of IFN-α and IFN-β (Samuel, 2001; Stark et al., 1998).  ORF45 has also been reported 
to interact with different cellular pathways that are essential for KSHV lytic replication (Zhu et 
al., 2006).  In addition to tegument proteins, mRNAs, spanning more than one kinetic class, have 
been shown to encapsidate into the virus particles of alpha and beta herpesviruses (Bresnahan 
and Shenk, 2000; Sciortino et al., 2001; Sciortino et al., 2002).  11 virally encoded RNAs in 
KSHV virions have been identified and are critical for the establishment and maintenance of 
KSHV latency (Bechtel, Grundhoff, and Ganem, 2005; Cai et. al., 2005).  The mechanism by 
which KSHV also possesses mRNAs within intact virions is not fully clear. 
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The Envelope 
The outermost layer KSHV virion envelope is made up of altered infected cellular membrane. 
The KSHV envelope is embedded with several glycoproteins designated as gB, gH, gpK8.1, gL, 
gM, gN and others (Koyano et al., 2003). A number of herpesviral glycoproteins play important 
roles throughout the viral lifecycle, including attachment, penetration, egress, and virus-induced 
cell fusion and tumorigenicity (Knipe et al., 2001). 
Kaposi’s Sarcoma-Associated Herpesvirus Lifecycle 
Viral Attachment and Entry 
Attachment of many enveloped viruses is a multistep process mediated by interactions between 
specific viral glycoproteins with receptors on the surface of the target cell.  Entry is the most 
critical step in the KSHV life cycle and greatly determines the pathogenesis of members of the 
herpesvirus family.  Entry of herpesvirus into a susceptible cell involves two steps:  the first step 
is virus binding to cell surfaces via viral envelope glycoproteins and cellular receptors (Spear and 
Longnecker, 2003).   The second step is fusion of the viral envelope with cellular membranes, 
releasing viral capsids into the cellular cytoplasm.  Alternatively, virions are internalized into 
endosomes with low pH in which the mildly acidic environment triggers viral glycoprotein-
induced fusion with the endosomes.  
Binding Receptors 
The initial binding to target cells of KSHV is mediated via KSHV envelope-associated 
glycoprotein gB and gpK8.1A, with ubiquitous heparan sulfate proteoglycan moieties on the 
surface of susceptible cells (Akula et al., 2001a; Akula et al., 2001b; Birkmann et al., 2001; 
Wang et al., 2001a).  In addition, KSHV interacts with the alphaVbeta3 integrin via the Arg-Gly-
Asp (RGD) motif of its glycoprotein B (Garrigues et al., 2008).  Heparan sulfate proteoglycans 
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covalently attach to glycosaminoglycans, abundantly distributed on the surface of mammalian 
cell membranes (Stringer and Gallagher, 1997).  Proteoglycans have key roles in various 
fundamental cellular processes including cell-to-cell adhesion, cell-to-matrix adhesion, cellular 
motility, cellular growth and cellular signaling transduction (Kjellen and Lindahl, 1991; Rostand 
and Esko, 1997).  The presence of heparan sulfate is not essential for virus entry, but it greatly 
increases the efficiency of virus entry into cells (Banfield et al., 1995).  
Herpesvirus viral attachment to cell surfaces is inhibited by soluble heparin, a molecule 
having a structure similar to heparin sulfate (Akula et al., 2001b).  Furthermore, the inhibition of 
KSHV particle entry into the cell cytoplasm by heparan is in a dose-dependent manner (Akula et 
al., 2001a; Birkmann et al., 2001; Wang et al., 2001a).  For the first time, it was shown that 
KSHV infected B cells are capable of preferentially using cellular (αV) or viral (gB) receptors to 
specifically bind cells, depending upon the stage of the cell cycle and infection.  Using the 
Matrigel system, KSHV infected PEL cells can attach to extracellular matrix proteins.  This 
attachment occurs preferentially in cells from S phase or cells from S phase actively supporting a 
lytic infection, respectively (Dyson et al., 2008).  
Entry Receptors 
The integrin receptor family has been indicated by a number of other viruses to be an entry 
pathway for infection.  Integrins control a wide variety of cellular functions that include cell 
survival, gene expression, cell cycle, actin dynamics, cell migration, angiogenesis, including cell 
attachment (Martin et al., 2002). 
 Several proteins have been reported to function as HHV-8 entry receptors.  KSHV 
infects a variety of cell types from different tissues and species, including B, T, endothelial, 
epithelial, fibroblast, keratinocyte cells, owl monkey kidney and baby hamster fibroblast cells 
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(Cerimele et al., 2001; Ciufo et al., 2001; Flore et al., 1998; Foreman et al., 1997; Gao, Deng, 
and Zhou, 2003; Kliche et al., 1998; Mesri et al., 1996).  This broad tropism for different cell 
types indicates a specific KSHV fusion-entry receptor(s) on the target cell surface. The cystine 
transporter, xCT, was identified as a KSHV fusion-entry receptor by functional cDNA selection 
(Kaleeba and Berger, 2006).   
Previous studies have shown that KSHV can successfully infect human monocytes and 
macrophages both in vitro and in vivo.  It has been recently reported that KSHV uses DC-SIGN 
(Dendritic cell-specific ICAM-3 grabbing nonintegrin; CD209) to enter macrophages and 
dendritic cells derived from monocytes (Rappocciolo et al., 2006).   DC-SIGN is a required 
receptor for HHV-8 infection of myeloid DCs and macrophages. Furthermore, infection of B 
cells was reduced by blocking DC-SIGN leading to the conclusion that the expression of DC-
SIGN is crucial for productive KSHV infection and replication in B cells (Rappocciolo et al., 
2008).  However, the KSHV viral proteins that interact with the xCT and DC-SIGN receptors 
have not yet been identified.  Moreover, a very recent study has shown that KSHV, as a human 
DNA tumor virus, specifically promoted TLR3 in human monocytes which until now has only 
been shown to be associated with the recognition of RNA viruses.  In this study, siRNAs directed 
against TLR3 significantly inhibited the ability of KSHV to up-regulate IFN-β1 and CXCL10 
(West and Damania, 2008).   
The integrin αVβ3 is a cellular receptor mediating both the cell adhesion and entry of 
KSHV into target cells through binding the RGD motif of virion-associated gB.  The αVβ3 is 
widely expressed in proliferating endothelial cells, arterial smooth muscle cells, and certain 
populations of leukocytes and tumor cells.  The integrin αVβ3 mediates the adhesion of cells to a 
number of extracellular matrix proteins containing RGD motifs, including vitronectin and 
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fibronectin, and being responsible for mediating cell-cell interactions through binding to cell-
associated glycoproteins containing RGD motifs.  In addition, αVβ3 has been reported as a 
receptor for the entry of target cells during the infection process by other viruses (Plow et al., 
2000).  In KS tumors, αVβ3 is highly expressed on KS tumor spindle cells and in neovascular 
endothelial cells and B cells that infiltrate KS tumors (Kaaya, Mwangi, and Ouna, 1996; Salcedo 
and Patarroyo, 1995; Uccini et al., 1994). These cells are also consistently infected with KSHV 
in KS lesions suggesting a central role for αVβ3 in KSHV infection and in the pathogenesis of 
KS.     
 
KSHV Latency 
One of the striking features of KSHV is the lifelong latent infection in host cells that modulates 
the host immune response.  Similar to other herpesviruses, KSHV has two modes of infection: 
latent (nonproductive) infection in which the viral genome persists in its host cell but with 
dramatically restricted gene expression and without cell destruction, and lytic (productive) 
Figure 1.1: KSHV Fusion and Entry. This illustration shows 
how KSHV fuses to and enters a human cell after binding to 
the protein xCT (Berger EA. Science. 2006 Mar 31; 
311(5769):1921-4.) 
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infection with progeny virions and the destruction of the host cell (Zhong et al., 1996).  In vivo, 
only less than 3% of infected cells in KS lesions or KSHV-positive lymphomas display evidence 
of lytic KSHV gene expression (Renne et al., 1996b).  Most commonly, KSHV infection remains 
in the latent state with very few genes expressed.   Host cell conditions play an important role in 
regulating both lytic and latent infections of target cells (Bryan, Dyson, and Akula, 2006; 
Mercader et al., 2000).  KSHV latent and lytic DNA replications are crucial and necessary for 
the long-term persistence of the virus. Moreover, both latent and lytic gene expression programs 
are involved in the pathogenesis of KSHV-related lymphoproliferative disorders (Cesarman, 
2002; Jenner and Boshoff, 2002).   
Lytic replication is necessary for the initial infection and replication of the virus in the 
host.  A productive lytic infection of herpesviruses leads to large amounts of virions and cell 
death via lysis. The lytic cycle has traditionally been thought not to contribute directly to 
oncogenesis because cells that enter this program invariably die.  KSHV readily transforms cells 
leading to tumorigenesis in vivo (Boshoff, 2002).  Lytic replication involves gene expression of 
virtually the entire viral genome.  Viral DNA replicates and produces infectious viral progeny 
leading to the death of host cells.  Lytic replication can be induced from latency by the induction 
of the transcription factor RTA (replication and transcription activator) (Lukac et al., 1998; Sun 
et al., 1998).  A recent study has suggested that KSHV RTA can regulate viral replication by 
promoting degradation of the suppressors, including K-RBP and HEY1 (Yada et al., 2006; Yang 
and Wood, 2007; Yang, Yan, and Wood, 2008).  K13 has been indicated to be able to block 
KSHV lytic replication via decreasing vIL-6 and hIL-6 expression (Zhao et al., 2007).  In 
addition, the induction of lytic replication can be also achieved by the treatment of latently 
- 24 - 
infected cells with phorbol esters or sodium butyrate or by transfection with consititutively active 
RTA alleles.   
EBV latent infection and the concomitant expression of the latent viral genes are essential 
for the development of EBV-related lymphoproliferative disorders (Griffin, 2000).  Like EBV, 
KSHV establishes a latent infection in the vast majority of tumor cells in Kaposi’s sarcoma 
lesions, thus implying that KSHV latent infection plays an essential role in the development of 
Kaposi’s sarcoma lesions (Moore and Chang, 2001).  Latent infection of KSHV is default in 
most host cells. Viral DNA exists as a circular episome in the nucleus and no progeny virions are 
produced.  In latency, viral gene expression is only limited to seven genes, including: LANA-1 
(ORF73), v-Cyclin D (ORF72), v-FLICE (K13), kaposin A (K12), v-IRF-2 (K11.5), LANA-2 
(K10.5) and LAMP (K15).  These latent genes have been shown to manifest both growth 
transforming and cell cycle-deregulating properties (Cotter and Robertson, 2002; Komatsu et al., 
2002). 
LANA-1 (latency-associated nuclear antigen) encoded by ORF73 is perhaps the most 
important latent gene expressed during the latent cycle.  LANA-1 is highly expressed in all 
latently infected tumor cells, indicating that LANA-1 plays a critical role in the maintenance of 
latent KSHV infection (Kedes et al., 1997; Kellam et al., 1997; Rainbow et al., 1997).  LANA-1 
has been shown to be a multifunctional protein and serves roles as the following: 1.) binds 
transcriptional corepressors (SAP30, Sin3A, CIR), 2.) possesses a nuclear localization motif, 3.) 
binds KSHV TR DNA cooperatively and supports terminal repeat (TR) directed viral replication, 
4.) associates with host cellular chromatin proteins and stays on the chromosomes during cell 
division, 5.) binds and inhibits p53 resulting in the inactivation of p53-dependent promoters, 6.) 
binds retinoblastoma protein RB1 leading to the induction of E2F-dependent genes, 7.) 
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transcriptionally activates EBV latency promoters, 8.) binds HIV-1 Tat, and 9.) binds to KSHV-
Rta by its direct binding to RBP-Jkappa (Dourmishev et al., 2003; Gonzalo et al., 2005; Lan, 
Kuppers, and Robertson, 2005; Lan et al., 2004). 
LANA-1, v-Cyclin D and v-FLICE (K13) are latent transcripts present and expressed 
from a differentially spliced polycistronic mRNA, in which their transcription is regulated via a 
common promoter (Cesarman et al., 1996a; Dittmer et al., 1998; Grundhoff and Ganem, 2001; 
Sarid et al., 1999; Talbot et al., 1999).  LANA-1 has been consistently shown to be the 
immunodominant latent antigen expressed in KS lesions (Dupin et al., 1999; Gao et al., 1996a; 
Gao et al., 1996b; Kedes et al., 1997; Kedes et al., 1996; Kellam et al., 1997; Rainbow et al., 
1997).  LANA-1 consists of 1162 amino acids and is identified as a 222–234 kDa 
phosphoprotein with an acidic internal repeat domain flanked by a carboxyl-terminal domain and 
an amino-terminal domain by Western blot analysis (Fakhari et al., 2006; Kellam et al., 1997; 
Rainbow et al., 1997).  LANA-1 displays a punctuated nuclear distribution pattern in 
immunohistochemical experiments (Gao et al., 1997).  LANA-1 can also activate its own 
promoter (Jeong, Papin, and Dittmer, 2001; Renne et al., 2001).  Viruses that establish latent 
infection must maintain their DNA in the host nucleus through many cellular generations; thus, 
KSHV must replicate its latent circular genome episomes before each cell division and then 
successfully segregate into progeny cells. 
KSHV latently infected cells harbor several copies of episomes.  In uninfected B 
lymphoblastoid cells, the expression of KSHV LANA-1 allows for the persistence of an episome 
containing the KSHV terminal repeat (TR) sequence.  During latency, LANA-1 binds 
specifically to the TR region of DNA repeat sequences consisting of 801 base-pair units and 
containing an origin of replication (OriP); thus showing a necessary and sufficient role for 
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LANA-1 in KSHV episome maintenance in transfected cells (Ballestas, Chatis, and Kaye, 1999; 
Ballestas and Kaye, 2001).  A short region in the C terminal part of LANA-1 has been 
demonstrated to be required LANA’s abilities, such as binding to and replication of viral 
episomes, modulation of transcription, and interaction with the members of Brd chromatin 
binding proteins Brd2/RING3 and Brd4s (Ottinger et al., 2006; Viejo-Borbolla et al., 2005; You 
et al., 2006).  The tethering of the KSHV genome by LANA-1 is also done by its interaction with 
host chromatin proteins such as histone H1, MeCP, DEK (Cotter, Subramanian, and Robertson, 
2001; Krithivas et al., 2002; Mattsson et al., 2002). Furthermore, LANA-1 has been shown to 
specifically bind KSHV TR DNA and allow for its replication (Cotter and Robertson, 1999; 
Cotter, Subramanian, and Robertson, 2001; Fejer et al., 2003; Grundhoff and Ganem, 2003; Hu, 
Garber, and Renne, 2002; Lim et al., 2002).  LANA-1 can mediate the inactivation of lytic cycle 
associated genes in the neighborhood of the terminal repeats through local interaction with 
SUV39H1.  SUV39H histone methyltransferases regulate a unique histone H3 lysine9 (H3–K9) 
methylation.  Trimethyl H3K9 is a marker of constitutive heterochromatin.   The chromatin 
protein SUV39H1 methylates the histone H-3 protein thus allowing for the heterochromatin 
protein 1 (HP-1) to bind to the methylated histone H-3 protein and expand the heterochromatin 
region (Aagaard et al., 1999; Bannister et al., 2001; Lachner et al., 2001).  LANA-1 also recruits 
de novo DNA methyltransferases DNMT3A that in turn bind to another euchromatic histone 
methyltransferase SETDB1/ESET, which can also trimethylate H3–K9 (Li et al., 2006; Shamay 
et al., 2006).  Unlike other KSHV promoters tested thus far, LANA promoter is not affected by 
tetradecanoyl phorbol acetate or viral lytic cycle functions.  However, it is subjected to control 
by LANA itself and cellular regulatory factors, such as p53. 
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Viral Gene Transcription and Expression 
Traditionally, transcription of herpesvirus genes are tightly regulated and sequentially ordered in 
a cascade fashion (Knipe et al., 2001). The sequentially ordered cascade of transcription occurs 
via a simultaneously and sequentially ordered viral protein cascade which modulates viral gene 
expression.  Herpesviruses use the host RNA polymerase and other members of the host 
transcriptional apparatus in order to execute its viral transcriptional program.  Transcription of 
herpesviral DNA occurs in the nucleus and the viral proteins are synthesized in the cytoplasm 
(Knipe et al., 2001).  Herpesviral genes are categorized into mutually exclusive latent and lytic 
profiles. This dichotomy of herpesviral gene transcription involves the latent phase which occurs 
while the viral genome is maintained as an episome and a lytic phase which takes place in a 
cascade fashion during productive (lytic) infection.  Upon establishment of a latent infection 
(nonproductive) only a few genes are expressed. During the course of a productive (lytic) 
herpesviral infection, approximately eighty genes are expressed.  Lytic infection of KSHV leads 
to cell lysis and therefore cell death, which is inconsistent with the establishment of KSHV 
transformation of the infected cell.  A substantially low level of KSHV infected PEL cultures 
undergo spontaneous lytic gene expression which could be readily detected in a stable milieu of 
PEL cultures that exhibit latent expression; the infrequent spontaneous KSHV-reactivation 
correlates well with the infrequent reactivation detected in KS clinical samples (Fakhari and 
Dittmer, 2002; Jenner et al., 2001; Paulose-Murphy et al., 2001; Sarid et al., 2001). The majority 
of infected cells in KS specimens exhibit latent KSHV gene expression, with a scant number of 
cells expressing lytic transcripts (Chan, Bloomer, and Chandran, 1998; Dupin et al., 1999; 
Katano et al., 2000) Lin, Dai, and Ricciardi, 1998; Orenstein et al., 1997; Parravicini et al., 2000; 
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Staskus et al., 1997; Sun et al., 1999); thus implying that, the low level of spontaneous lytic gene 
expression is not an artifact of tissue culture models. 
Recently, models of de novo infections of cultured endothelial cells have also manifested 
a similar “hodge-podge” pattern of latent and lytic gene expression (Ciufo et al., 2001; Lagunoff 
et al., 2002; Moses et al., 1999).  Both latent and lytic cycle replication are crucial for the long-
term persistence of the virus, and gene products from both latent and lytic gene expression 
programs have been implicated in the pathogenesis of KSHV associated disorders (Cesarman, 
2002; Jenner and Boshoff, 2002).  
Classification of the latent or lytic gene expression of individual KSHV ORFs would 
serve an immense role in the prediction of their potential contribution to the pathogenesis of the 
KSHV infection. The facilitation of cultured PEL cells latently infected with KSHV and 
inducing lytic reactivation with common laboratory chemicals (such as phorbol esters or sodium 
butyrate) have led to clear designations of individual KSHV genes as either latent or lytic genes.  
Typically, PEL cell lines (in which every cell in the PEL culture is infected with KSHV) carry 
approximately 40 to 150 copies of KSHV DNA per cell genome (Drexler et al., 1998). Upon 
routine passage of the PELs, the virus is consistently maintained as a latent episome, with 
concomitant restriction of lytic viral gene expression and a paucity of virus production. Upon 
chemical induction of PELs, viral gene expression switches from the latent program to an 
ordered cascade of lytic gene expression, leading to viral replication, virion production, cell 
lysis, and viral release (Renne et al., 1996a; Renne et al., 1996b; Sarid et al., 1998; Zhong et al., 
1996). 
The expression pattern of each KSHV ORF was categorized into three classes of gene 
transcription: I, II, and III.  The assignation of each ORF to its respective class was determined 
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by the individual gene response to the addition of TPA to PEL cultures (Sarid et al., 1998).  
Class I transcripts are constitutively expressed and are not induced by phorbol esters.  Class I 
gene transcripts correspond directly with the latent gene expression profile, which includes 
ORF73 (LANA-1), ORF72 (viral cyclin D [vCyc]) and K13 (fas-ligand IL-1 β-converting 
enzyme inhibitory protein [vFLIP]); these proteins are readily detected in KS samples, further 
establishing the categorization within the latent phase of the KSHV transcriptional program 
(Davis et al., 1997; Dittmer et al., 1998).  The three class I KSHV-ORFs have corresponding 
sequence homologs in HVS (Nicholas, Cameron, and Honess, 1992; Thome et al., 1997), and 
their respective expressed proteins serve crucial roles in latency and cellular transformation 
(Dourmishev et al., 2003).  ORF K13 (vFLIP) encodes a viral inhibitor of a cellular homologue 
of the Fas-mediated apoptosis (Thome et al., 1997).  ORF 72 (vCyc) encodes a functional cyclin 
D homolog which could substitute for human cyclin D by phosphorylating the retinoblastoma 
tumor suppressor protein (Chang et al., 1996).  ORF73 (LANA-1) encodes LANA (Rainbow et 
al., 1997), a highly immunogenic protein that is highly expressed and is the basis for both 
immunofluorescence and Western assay-based serological tests (Gao et al., 1996a).   
The class II gene transcription includes mRNAs which are detected in variable abundance 
of high, moderate, or low in cultures grown under standard growth conditions without phorbol 
esters.  In addition, the class II transcripts could be readily induced to higher levels of 
transcription by TPA (Sarid et al., 1998).  Examples of class II mRNAs that are transcribed at 
moderate levels without TPA treatment include the following: cytokines v-IL-6 (ORF K2), v-
MIP-II (ORF K4), and v-IRF (ORF K9).  A true latent transcription is restricted in both PEL and 
KS lesions.  However, a number of genes are expressed, generally at low transcription levels, in 
PEL without TPA treatment and are inducible with TPA (class II).  The majority of class II genes 
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contain typical herpesviral regulatory and viral DNA replicative genes, along with a majority of 
the viral homologs of cellular genes (Sarid et al., 1998).  Interestingly, the class II category of 
transcription includes many unique KSHV genes (e.g., the viral cytokines and v-IRF), thus these 
transcripts serve essential roles in the manipulation of cellular pathways, regulation of viral 
infection and transformation of the host cell (Gao et al., 1997; Moore and Chang, 1998).  Both 
class I and II genes are the least conserved among all herpesviruses, and these genes tend to 
cluster within the same region of the KSHV genome containing regulatory genes that are also 
referred to as “latency islands” (Moore et al., 1996a; Moore and Chang, 2001).   
The final class of gene transcription, class III, involves transcripts that could only be 
detected after induction with phorbol esters (Sarid et al., 1998).  Class III transcripts include lytic 
genes which are transcribed during active infection and are necessary for efficient viral lytic 
replication and virion particle production including the following transcripts: ORF 25 (major 
capsid protein), ORF 6 (DNApolymerase), and ORF 22 (glycoprotein H) (Sarid et al., 1998).  
Many class III genes are highly conserved among all herpesviruses and possess functional roles 
in DNA replication and virion morphogenesis (Knipe et al., 2001; Sarid et al., 1998). 
Reactivation 
Typically in traditional herpes simplex virus infections (the prototype herpesvirus), a tegument 
protein localizes to the nucleus and activates the immediate early gene expression, which in turn 
commences the sequentially ordered cascade of viral gene expression characteristic of 
herpesviruses (Knipe et al., 2001).  The two human gamma herpesviruses, EBV and KSHV, 
manifest similar patterns of the latent and lytic phases of infection, and both of these gamma 
herpesviruses require a reactivation mechanism in order to switch from the latency phase to the 
lytic phase.  KSHV latency is critical in the establishment of a permanent infection both in vitro 
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and in vivo.  The latency phase allows for the virus to evase host immune surveillance and 
establishes long-term and persistent infection (Moore and Chang, 2003).  In addition, latent 
infection by either KSHV or EBV plays a major role in tumorigenesis (Cesarman, 2002; Chang 
and Moore, 1996).  To establish latent infection in susceptible cells, viral reactivation must 
overcome a stringent regulation of viral gene expression, since KSHV viral gene expression is 
highly limited and tightly controlled.  KSHV spontaneously reactivates in infected cells and the 
process of viral lytic replication begins.  Both tetradecanoyl phorbol acetate (TPA) and sodium 
butyrate (NaB) have been shown to disrupt the latency of KSHV in BCBL-1 cells and induce 
lytic viral replication (Arvanitakis et al., 1996; Renne et al., 1996b; Yu et al., 1999).   
Many recent studies have demonstrated that cell cycle progression has a role in 
reactivation of KSHV infection (Bryan, Dyson, and Akula, 2006; McAllister et al., 2005).  A 
direct correlation between cell cycle progression, KSHV reactivation and cell-surface topology 
has also been observed (Whitman et al., 2007).  In this study, the KSHV-infected cells in G0/1 
phase had finger-like projections on their surface, while cells in S phase had a relatively smooth 
cell surface.  Furthermore, a very recent study has suggested that cell cycle has an effect on the 
expression of cellular receptors utilized by KSHV. This study indicated that KSH-infected 
human B cells can preferentially use cellular αV integrin or viral receptors to specifically bind 
cells, depending upon the stage of the cell cycle and infection (Dyson et al., 2008).    
As mentioned in the previous section, five latent genes are expressed during latency: 1.) 
LANA-1, 2.) v-cyclin, 3.) v-FLIP, 4.) kaposin, and 5.) vIRF-2 (Burysek and Pitha, 2001; Dittmer 
et al., 1998; Muralidhar et al., 1998; Muralidhar et al., 2000; Rainbow et al., 1997; Sadler et al., 
1999; Saveliev, Zhu, and Yuan, 2002).  The expression profile of these latent genes serves a 
crucial role in the maintenance of latency and cellular transformation.  Lytic reactivation of a low 
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percentage of infected cells is necessary for KS development (Lukac, Kirshner, and Ganem, 
1999; Martin and Osmond, 1999; Whitby et al., 1995).  Evidence over the years clearly suggests 
roles for reactivation and/or lytic replication in the pathogenesis and induction of KS tumors: 1.)  
 
Figure 1.2: KSHV Gene Map.  The virus can then either enter a latent program, in which the 
viral episome is maintained and no virions are produced, or enter a lytic program, in which viral 
particles are produced and the host cells are lysed.  During the latent program, a small number of 
proteins (indicated in green) are expressed to maintain the viral episome, to avoid host antiviral 
immune responses and to provide a growth advantage to infected cells.  Latently infected cells 
can be induced to enter the lytic cycle under specific physiological conditions.  The factors that 
regulate the switch from the latent to the lytic cycle have not yet been fully characterized, but 
they involve the viral proteins replication and transcriptional activator (RTA; encoded by open 
reading frame 50 (ORF50)) and ORF57, as well as recombination signal binding protein for 
immunoglobulin J  region (RBP-J ), a transcription factor downstream of the Notch signalling 
pathway.  Lytic replication leads to extensive viral gene expression.  Lytic gene expression is 
tightly regulated (viral genes transcribed early upon reactivation are indicated in yellow, those 
transcribed during intermediate kinetics in orange, and those transcribed during late kinetics in 
red).  KSHV-encoded microRNAs are indicated by grey arrowheads (Laurent Coscoy. ature 
Reviews Immunology. 2007 May, 7,391-401). 
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linkage between the humoral immune response to KSHV infection and KS tumor progression 
(Whitby et al., 1995); 2.) augmentation of KSHV viral load in patients correlates with 
progression from asymptomatic phase to KS (Ambroziak et al., 1995); 3.) patients dually 
infected with both KSHV and HIV when treated with ganciclovir, a drug that effectively targets 
KSHV lytic replication, leads to a decreased incidence of KS development (Martin and Osmond, 
1999); 4.) both KS tumor cells (typically manifest a latent KSHV infection) and KSHV infected 
spindle cells (also typically manifest in latent KSHV infection), KS tumor cells and KSHV 
infected spindle cells consistently undergo spontaneous reactivation of concomitant lytic 
replication from latent cells in a small population (Reed et al., 1998; Staskus et al., 1999; Staskus 
et al., 1997; Zhong et al., 1996).  Viral lytic reactivation and DNA replication are considered 
crucial in KSHV spread from the lymphoid reservoir B cells to endothelial cells and the 
sequential KS spindle cell formation (Offermann, 1999).  Hence the reactivation mechanisms 
regulating the switch from latent to lytic replication in KSHV infected cells serve an essential 
role in the development of KS and the KSHV-related lymphoproliferative disorders.  
Regulation of Transcriptional Activation 
Upon chemical induction, KSHV expresses viral transcription activator proteins such as ORF50 
and K8, which are important for the induction of lytic replication (Zhu, Cusano, and Yuan, 
1999).  The viral immediate-early transactivator Rta/Orf50 is necessary and sufficient for virus 
reactivation and lytic replication (Gradoville et al., 2000; Lukac, Kirshner, and Ganem, 1999; 
Lukac et al., 1998; Sun et al., 1998).  Initially, KSHV-Rta was identified based on positional 
analogies and sequence homology with EBV and HVS (Sun et al., 1998).  The KSHV-Rta is one 
of the earliest immediate-early transcripts induced upon viral reactivation and expressed earlier 
than K8 (Sarid et al., 1998; Sun et al., 1999; Zhu, Cusano, and Yuan, 1999).  The major ORF50 
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transcript is a tricistronic mRNA, which also encodes the genes ORF-K8 (K-bZIP/RAP) and 
ORF-K8.1 (K8.1 glycoprotein) (Gruffat et al., 1999; Lin et al., 1999; Lukac et al., 1998; Seaman 
et al., 1999; Sun et al., 1998; Zhu, Cusano, and Yuan, 1999).  Alternative splicing mechanisms of 
the neighboring exons of this tricistron also lead to the expression of two minor tricistronic 
transcripts (Zhu, Cusano, and Yuan, 1999).  The K-bZIP or RAP (ORF-K8) transcript is also 
produced with immediate-early kinetics independently of the upstream ORF50 gene (Saveliev, 
Zhu, and Yuan, 2002).  In clinical samples, the Rta is detected corresponding with the lytic 
pattern in KS lesions (Katano et al., 2001; Sun et al., 1999).  The 691 amino acid Rta has been 
shown to be highly post-translationally modified and extensively phosphorylated (Lukac, 
Kirshner, and Ganem, 1999; Lukac et al., 1998).  A number of transfection experiments have 
indicated that Rta is capable of transactivating KSHV promoters of genes that are typically 
expressed upon a productive lytic infection (Chang et al., 2002; Chen et al., 2000; Jeong, Papin, 
and Dittmer, 2001; Lukac and Alwine, 1999; Lukac, Kirshner, and Ganem, 1999; Lukac et al., 
1998; Song et al., 2001) Song et al., 2001; Wang et al., 2001b; Zhang, Chiu, and Lin, 1998).  Rta 
possesses a transcriptional activation domain located at its carboxyl terminus domain which 
exhibits a similar structure conserved among several eukaryotic transcriptional activation 
domains (Lukac et al., 1998).  Deletion of this transcriptional activation domain generates an 
Rta-specific dominant negative inhibitor of transactivation Rta.  When transfected into BCBL-1 
cells, this Rta-specific dominant negative inhibitor of transactivation Rta would effectively 
suppress spontaneous lytic reactivation from latency along with reduction of viral replication 
induced by the following chemical agents: TPA, sodium butyrate, and ionomycin (Lukac, 
Kirshner, and Ganem, 1999).   
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Rta binds directly to various viral promoters with specific sequences (Chang et al., 2002; 
Deng et al., 2002a; Liang et al., 2002; Lukac et al., 2001; Song et al., 2001; Song et al., 2002).  
The major targets of Rta transactivation are considered essential for lytic replication. Rta has 
been shown to transactivate the following genes which are considered essential for viral 
subversion of the normal regulatory cell growth mechanism: kaposin, vIL-6, vMIP-I, vIRF-1, 
vGPCR, and K1(Bowser, DeWire, and Damania, 2002; Chen et al., 2000; Curreli et al., 2002; 
Deng et al., 2002b; Ueda et al., 2002; Wang et al., 2001).  The significance of Rta in the 
dysregulation of cellular growth pathways is shown by Rta-mediated activation of cellular IL-6 
(Deng et al., 2002a), the ability of Rta to block p53-mediated apoptosis via competitive binding 
to CBP (Gwack et al., 2001).  Concordant with the orchestration of the KSHV lytic cycle by Rta 
with concomitant manifestation of pathogenic progression, a clinical study has shown the Rta 
promoter is repressed by methylation.  When demethylized, the promoter latent KSHV genome 
is induced and lytic replication begins (Chen et al., 2001).  Furthermore, more evidences have 
shown that many cellular and viral proteins, including K-RBP, are capable of repressing RTA-
mediated transactivation and KSHV lytic replication.  Herpes simplex virus type 1 transactivator 
ICP0 and human cytomegalovirus transactivator pp71 also stimulate the degradation of 
repressors in the host.  Recently, KSHV RTA has been demonstrated to regulate lytic replication 
by promoting the degradation of the repressor K-RBP (Yang, Yan, and Wood, 2008).  Therefore, 
silencer degradation by viral transactivators may be a common mechanism for regulating the 
lytic replication of herpesviruses. 
K-bZIP, a leucine zipper-containing transcription factor encoded by ORF K8 can 
modulate viral and cellular gene expression and affect host cell functions.  K-bZIP nuclear 
protein (Zhao et al., 2007) interacts with and represses RTA-mediated transactivation of viral 
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promoters, including that of the K8 gene.  A recent study has suggested that a new role for K-
bZIP is that it competitively binds to the interferon-responsive factor 3 elements leading to 
immune evasion (Lefort et al., 2007).  
Viral DA Replication 
As a gamma-herpesvirus, KSHV possesses both latent and lytic replication cycles (Miller et al., 
1997; Renne et al., 1996).  However, latency expresses only a small number of viral genes, and 
no infectious virus is produced during this phase.  In KSHV latently infected cells, multiple 
copies of the viral genome are harbored and maintained as extrachromosomal episomes, and 
latent KSHV DNA replication is synchronized with host cell division (Ballestas, Chatis, and 
Kaye, 1999)  The terminal repeat (TR) sequence in the KSHV genome is necessary and 
sufficient for persistence of the viral episome and potentially serves as the origin of latent 
plasmid replication (ori-P) (Ballestas and Kaye, 2001).  LANA-1 binds to cis-acting region 
within the KSHV TR DNA and trans-acting on the ori-P to mediate episome persistence 
(Ballestas and Kaye, 2001).  Upon KSHV reactivation with the concomitant disruption of 
latency, the virus switches to a lytic life cycle which facilitates its lytic encoded replication 
proteins (Miller et al., 1997; Renne et al., 1996a).  During the viral lytic replication, KSHV 
expresses the majority of its genes, and viral DNA is amplified by a viral encoded replication 
apparatus different from the latent viral DNA replication (Gradoville et al., 2000; Wu et al., 
2001). 
In herpesviruses, lytic DNA replication is different in two aspects from the latent DNA 
replication.  First, upon lytic DNA replication, viral DNA is amplified from a range of 100 to a 
1,000-fold via a rolling circle mechanism, which produces viral progeny in concatemeric 
molecules also known as “head-to-tail” concatemers (Knipe et al., 2001).  In contrast to this 
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rolling circle replication during viral lytic phase, latent DNA replication occurs simultaneously 
with the host cell division and sequentially maintains a stable and low number of viral episomes.  
Secondly, lytic herpesviral DNA replication requires virally encoded replication proteins with its 
own DNA polymerase and related viral components of the replication apparatus (Knipe et al., 
2001).  The herpesviral-encoded lytic replication apparatus is another distinction from the 
herpesviral latent DNA replication which requires the host cellular DNA polymerase along with 
its accessory proteins. 
The herpesviral lytic DNA replication is initiated from an origin (ori-Lyt) and requires 
many viral gene products.  The ori-Lyt is bound by a virus encoded origin-binding protein (OBP) 
that recruits the core replication machinery.  A number of herpesvirus lytic origins have been 
identified and characterized (Anders et al., 1992; Anders and Punturieri, 1991; AuCoin et al., 
2002; Hammerschmidt and Sugden, 1988; Pari et al., 2001; Stow, 1982; Stow and Davison, 
1986).  These studies indicate several common features that have been identified within the 
herpesviral lytic origins; for example they are rich in AT regions.  These AT-rich regions are 
presumably sites where DNA is melted or unwound, numerous transcription factor-binding sites, 
and promoter enhancer elements are associated with active transcription or assembly of the 
transcription machinery.  In the KSHV genome, two copies of the lytic DNA replication origin 
[ori-Lyt (L) and ori-Lyt (R)] have been identified (AuCoin et al., 2002; Lin et al., 2003).  The 
first ori-Lyt is located in the KSHV genome between K4.2 and K5, while the second ori-Lyt is 
located between K12 and open reading frame 71 (ORF71).  KSHV lytic origins closely resemble 
the lytic origin of a related Herpesvirus, rhesus macaque rhadinovirus (RRV) (Pari et al., 2001).  
Both RRV and KSHV lytic origins have GC-rich regions proximal to an AT-rich region.  Initial 
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mapping studies indicated that replication was dependent on the presence of the AT-rich region 
and a portion of the GC-rich region (AuCoin et al., 2002; Pari et al., 2001).   
The lytic herpesviral replication apparatus involving all of its necessary viral trans-acting 
factors required for origin dependent DNA replication has been described for the Epstein-Barr 
virus (EBV), human cytomegalovirus (HCMV), and herpes simplex virus type 1 (HSV-1) using 
a transient co-transfection replication assay (AuCoin et al., 2004; Fixman, Hayward, and 
Hayward, 1995; Pari et al., 2001; Sarisky and Hayward, 1996; Wang, Zhang, and Montalvo, 
1998; Wu et al., 1988).  Six core replication proteins are required for ori-Lyt-dependent DNA 
replication spanning the three herpesviral subfamilies.  These proteins include DNA polymerase, 
processivity factor, helicase, primase, primase-associated factor, and ssDNA binding protein 
(Knipe et al., 2001).  The KSHV genome encodes a set of six genes which have various levels of 
homology to their respective core replication gene counterparts in EBV, HSV, and HCMV.  The 
six KSHV core replication proteins are listed as follows: ORF9 (POL; DNA polymerase), 
ORF59 (PPF; polymerase processivity factor or DNA replication protein), ORF6 (SSB; single-
stranded DNA binding protein), ORF56 (PRI; component of DNA helicase-primase complex), 
ORF40/41 (PAF; polymerase accessory factor), and ORF44 (HEL; component helicase-primase 
complex).  Importantly, each herpesvirus encodes an initiator protein or an origin binding 
protein, which allows the viral replication proteins to assemble and dock onto the ori-Lyt.  The 
Zta protein is essential for EBV origin-dependent DNA replication and serves to activate 
transcription as well as play a direct role in DNA replication (Chang et al., 1990; Sarisky and 
Hayward, 1996).  The KSHV RTA has been shown to be sufficient for KSHV viral reactivation 
but indispensable for viral DNA replication.  Rta serves as the major transactivator of gene 
expression recruiting the pre-replication complexes to ori-Lyt DNA.  RTA interacts with the 
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RRE and bZIP (K8, RAP), which binds to a cluster of C/EBP binding motifs with the aid of 
C/EBP alpha (Lin et al., 2003; Wang et al., 2006).  Several cellular factors associated with ori-
Lyt have been identified by using DNA affinity purification and mass spectrometry.  These 
cellular proteins that bind to KSHV ori-Lyt include topoisomerases (Topo) I and II, MSH2/6, 
RecQL, poly (ADP-ribose) polymerase I (PARP-1), DNA-PK, Ku86/70 autoantigens, and 
scaffold attachment factor A (SAF-A) (Wang et al., 2008). 
KSHV Glycoproteins and Their Putative Functions 
The Kaposi’s sarcoma-associated herpesvirus genome encodes several glycoproteins, some of 
which possess significant homology with glycoproteins of other herpesviruses.  These include 
glycoprotein B (gB) (ORF8), gH (ORF22), gM (ORF39), gL (ORF47) (Neipel, Albrecht, and 
Fleckenstein, 1997; Russo et al., 1996), and gN (ORF53) (Koyano et al., 2003).  In addition, 
KSHV encodes glycoprotein gpK8.1A, gpK8.1B, K1, vOX2 (K14) and K15 during lytic 
replication with no counterparts in other herpesviruses (Chandran et al., 1998a; Chandran et al., 
1998b; Chung et al., 2002; Neipel et al., 1997; Schulz, 1998b).  Glycoproteins serve various 
functions at key points along viral replication including virus attachment, penetration, cell-to-cell 
spread, egress, and virus-induced cell fusion.  This section will review the features of these 
glycoproteins and describe the putative functions associated with each glycoprotein.  
Glycoprotein B (gB) 
Glycoprotein B (gB) is one of the most conserved glycoproteins across all subfamilies of 
herpesviruses.  Moreover, the carboxyl-tail domain of gB exhibits the highest degree of 
conserved homology within the gB molecule (Goltz et al., 1994; Pereira, 1994; Ross et al., 
1989).  gB is essential for members of the alpha- and betaherpesvirus subfamilies.  gB expresses 
on the surface of host cells or on virion envelopes as a homodimeric membrane protein 
- 40 - 
(Claesson-Welsh and Spear, 1986; Claesson-Welsh and Spear, 1987; Horsburgh et al., 1999; 
Ligas and Johnson, 1988; Roop, Hutchinson, and Johnson, 1993; Spear and Longnecker, 2003).   
gB is the product of the KSHV-ORF8 (Russo et al., 1996).  The KSHV-gB molecule is 
classified as a type I integral membrane protein, 845 amino acids in length, consisting of four 
domains: 1.) signal peptide domain, 2.) ectodomain (exposed towards the outside of the cell), 3.) 
transmembrane domain, and 4.) carboxyl-tail domain (located within the cytosol).  The first 
putative signal sequence of 23 amino acids (a.a) of KSHV-gB is an extracellular domain 
containing multiple glycsylation sites and multiple hydrophobic regions, of which the carboxyl-
most terminal region keeps gB in the membrane (Baghian et al., 2000; Pertel, 2002; Pertel, Spear, 
and Longnecker, 1998).  The amino acids 733 through 752 constitute the transmembrane 
domain, the amino acid 703 is ectodomain and the 93 a.a composes carboxyl terminal tail (Wang 
et al., 2003).  The carboxyl tail of KSHV-gB displays similar characteristics to the cytoplasmic 
terminal domain of HSV1-gB, in which the hydrophilic amino acid residues in this region are 
positively charged (Pellett et al., 1985; Pertel, Spear, and Longnecker, 1998).  Based on its 
primary structure the predicted molecular weight of KSHV-gB would be expected to be 91.3 
kDa.  However, studies have shown that a fully processed gB could be detected well over 100 
kDa (Akula et al., 2001a; Baghian et al., 2000; Pertel, Spear, and Longnecker, 1998).  
Glycosylation inhibition experiments have clearly shown that KSHV-gB contains predominantly 
N-linked carbohydrates (Baghian et al., 2000; Pertel, Spear, and Longnecker, 1998).  In virions 
produced from BCBL-1 cells, the virion envelope-associated gB can be detected on the surface 
of both infected cells and the virion envelope (Akula et al., 2001a; Baghian et al., 2000).  Virion 
envelope-associated gB has also been shown to have strong affinity for heparan by experiments 
in which KSHV gB binds to heparan-agarose beads with a biotinylated peptide of a gB-heparan 
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binding domain (gB-HBD peptide consisted of the following 108-117 gB-a.a. sequence: 
HIFKVRRYRK binds) in a dose-dependent manner to BSA-Heparan coated 96 well plates 
(Akula et al., 2001a). 
A number of studies indicate that gB plays important roles in virion attachment and virus 
entry into susceptible cells: HSV-1 mutant viruses lacking gB are not able to enter into cells (Cai 
et al., 1987), this is because of the lack of post-attachment that can be resolved by polyethylene 
glycol mediated fusion of viral envelopes with cellular membranes (Cai, Gu, and Person, 1988).  
Point mutagenesis, in which single amino acid substitutions and/or truncations of the carboxyl 
terminus of gB occur, causes extensive virus-induced cell fusion (Baghian et al., 1993; Bzik et 
al., 1984; Cai et al., 1988; Haan, Lee, and Longnecker, 2001).  Transient transfection 
experiments showed that the transient co-expression of HSV-1 gB along with gD, gH and gL 
causes cell-to-cell fusion, which is substantially increased by carboxyl terminal truncations of gB 
(Highlander et al., 1991; Kousoulas, Person, and Holland, 1978; Pogue-Geile et al., 1984).  
Similarly, transient transfection experiments using KSHV-gB along with gH and gL were 
sufficient to cause cell-to-cell fusion.  However, deletion of the final 59 a.a of the KSHV-gB 
carboxyl tail (termed gB-Mut) substantially enhanced cell-to-cell fusion (Baghian et al, personal 
communication). These results suggest a direct role for gB in membrane fusion and suggest that 
perturbations of the carboxyl terminal domains of gB facilitate gB-mediated cell-to-cell fusion.  
Interestingly, our work on siRNA-mediated silencing of gB carboxyl terminal truncations 
showed that the carboxyl terminus of gB is indispensable for virus egress from infected cells and 
infectivity.  KSHV virions incorporate gB in the viral envelope, which is important for 
attachment to cell surfaces and entry via the RGD motif. 
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The α3β1 integrin was first implicated (Akula et al., 2001) as one of the cellular receptors 
utilized by KSHV for viral entry into susceptible cells.  KSHV was the first herpesvirus shown to 
utilize integrin as a cellular receptor for target cells (Akula et al., 2002; Nemerow and Cheresh, 
2002).  The RGD (Arg-Gly-Asp) amino acids constitute a motif which is necessary for a myriad 
of cellular ligands that bind to host cell surface integrin molecules (Plow et al., 2000).  The RGD 
motif (27-29 a.a.) is immediately behind the KSHV-gB signal peptide.  Interestingly, not all 
herpesvirus gBs possess the gB-integrin interaction since there has been no other gB in the entire 
Herpesviridae family that has a similar conserved RGD motif.  Integrin α3β1 is broadly 
expressed and has been detected on all cells susceptible to infection by HHV-8, including human 
foreskin fibroblasts (HFF) and B, epithelial, endothelial, and 293 cells (Akula et al., 2002; Plow 
et al., 2000; Wu and Dedhar, 2001).  It is also very interesting that at similar concentrations used 
for the above mentioned virus neutralization experiments, RGD peptides, RGD-gB antibodies, 
anti-integrin antibodies and soluble integrin α3β1 proteins could not inhibit KSHV binding to 
HFF cells while soluble heparan almost completely blocked viral attachment.  These results 
suggested a post-attachment role for the gB/integrin interaction, in which gB binding to the 
integrin receptor was able to facilitate viral entry into susceptible cells (Akula et al., 2002).  
Furthermore, the inability of these molecules to completely neutralize viral infectivity implied 
the potentially other cellular receptors utilized by KSHV for entry.  However, a recent study has 
indicated that cell activity was not correlated with surface expression of integrin α3β1, 
suggesting the presence of a putative KSHV fusion-entry receptor (Kaleeba and Berger, 2006).  
A very recent study has demonstrated that αVβ3 is a cellular receptor mediating both the cell 
adhesion and entry of KSHV into target cells through binding the RGD motif of virion-
associated gB (Garrigues et al., 2008).  Envelope-associated KSHV-gB clearly binds to both 
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heparan sulfate receptors (HS) and integrin αVβ3 which are located on the surface of target cells, 
thus two different motifs (HBD and RGD) of KSHV-gB mediates KSHV virions binding via HS 
and viral entry via integrin αVβ3 cellular receptor, respectively (Akula et al., 2001a; Akula et al., 
2002; Akula et al., 2001b; Garrigues et al., 2008). Interestingly, the binding of soluble gB 
proteins to target HFF cells induce morphological changes, e.g., cell rounding and detachment, 
while these cells remained viable with no noticeable cellular death (Akula et al., 2003).  These 
results are consistent with the morphological changes noticed by integrin-mediated clumping of 
integrin molecules with concomitant rearrangement of the actin cytoskeleton (van der Flier and 
Sonnenberg, 2001). 
KSHV K8.1 
KSHV glycoproteins gB and K8.1A mediate initial binding of virions onto glycosaminoglycans, 
e.g. heparan sulfate on cell surfaces (Akula et al., 2001a; Akula et al., 2001b; Birkmann et al., 
2001; Wang et al., 2001a).  Consistent with the strong binding of purified K8.1A to heparan 
sulfate moieties on cell surfaces, initial studies showed that a soluble form of K8.1A inhibited 
KSHV attachment onto cells (Wang et al., 2001a). However, a later report indicated that a 
similar soluble form of K8.1A did not block KSHV infectivity (Birkmann et al., 2001).  In 
addition, gB binds to integrins, such as αVβ3 membrane receptors through a RGD motif, 
suggesting that integrins function as cellular receptors for KSHV entry (Naranatt et al., 2003).  
However, soluble integrins or RGD-containing peptides failed to inhibit virus entry into 293 cells 
(Inoue et al., 2003). 
There are two ORFs originating from the K8.1 gene via spliced transcripts, K8.1A and 
K8.1B.  The K8.1A cDNA encodes a 228 a.a protein containing a signal sequence, 
transmembrane domain and four N-glycosylation sites.  The K8.1B cDNA encodes a 167 a.a 
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glycoprotein sharing similar amino acids and carboxyl termini with K8.1A but contains an in-
frame deletion (Chandran et al., 1998a; Raab et al., 1998).  K8.1A is the predominant form 
detected within infected cells and the virion envelopes (Zhu, Puri, and Chandran, 1999).  One of 
the striking features of the K8.1 gene is that it is co-linear to the EBV major glycoprotein 
gp350/220 (Gong and Kieff, 1990), gp150 of murine gammaherpesvirus 68 (MHV 68) (Stewart 
et al., 1996), herpesvirus saimiri (HVS) ORF 51 gene and the BOEFD1 gene of bovine 
herpesvirus-4 (BHV-4) (Albrecht et al., 1992; Neipel, Albrecht, and Fleckenstein, 1997; Russo et 
al., 1996).  EBV gp350/220 has been shown to be involved in the binding of the virus to the 
target cells via the CD21 receptor on B cells (Fingeroth et al., 1984; Nemerow et al., 1989; 
Nemerow et al., 1987; Nemerow et al., 1985; Tanner et al., 1987).  However, gp350/220 is not 
required for virus entry into fibroblasts (Janz et al., 2000).  By using the recombinant KSHV 
BAC36 system, glycoproteins K8.1 have been indicated to be dispensable for viral entry (Luna et 
al., 2004).  
Glycoprotein H (gH) and Glycoprotein L (gL) 
The products of the KSHV-ORF22 and KSHV-ORF47, gH and gL respectively form 
heterodimers, which are components of the virion envelope (Naranatt, Akula, and Chandran, 
2002).  The virion envelope embedded glycoprotein H (gH) has been highly conserved among all 
members of the herpesvirus family, gH has been shown to be essential for virus penetration and 
cell-to-cell spread (Babic et al., 1996; Duus, Hatfield, and Grose, 1995; Forghani, Ni, and Grose, 
1994; Fuller, Santos, and Spear, 1989; Haddad and Hutt-Fletcher, 1989; Hutchinson et al., 1992; 
Lomonte et al., 1997; Mukai et al., 1997).  Expression of gH in the absence of gL leads to a 
protein that is incorrectly folded and processed.  Heterodimeric complex formation between gH 
and gL is a common theme among herpesviruses: Herpes simplex virus-type1 (HSV-1) 
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(Hutchinson et al., 1992), varicella zoster virus (VZV) (Forghani, Ni, and Grose, 1994), human 
cytomegalovirus (HCMV) (Kaye, Gompels, and Minson, 1992), human herpesvirus 6 (HHV-6) 
(Liu et al., 1993), HHV-7 (Mukai et al., 1997), Epstein-Barr virus (EBV) (Yaswen et al., 1993).  
However, a heterocomplex of the gH, gL, and gp42 complex formed in EBV is required for the 
infectivity of B cells; although, gp42 is not required for the infectivity of epithelial cells (Li, 
Turk, and Hutt-Fletcher, 1995). 
Many studies have shown that gH is the only viral fusion glycoprotein displaying typical 
structural-functional features.  Coiled-coil domains in gB and gH have been indicated to be 
associated with human cytomegalovirus membrane fusion (Lopper and Compton, 2004).  It has 
been reported that the ectodomain of HSV-1 gH contains a hydrophobic membrane alpha-helix 
(residues 377 to 397) with attributes of an internal fusion peptide (Gianni et al., 2005; Gianni, 
Menotti, and Campadelli-Fiume, 2005).  Moreover, heptad repeat 1 (HR, residues 443 to 471) 
with a high propensity to form a coiled-coil located downstream of this alpha-helix and plays 
critical role in virus entry and fusion (Gianni et al., 2006a).  HR-2 of gH interacts with HR-1 and 
serves critical roles in virus entry and fusion.  Complex formation between HR-1 and HR-2 is 
independent of the presence of adjacent gH sequences and of additional glycoproteins involved 
in entry and fusion (Gianni et al., 2006b).  Hydrophobic alpha-helices 1 and 2 of gH are capable 
of interacting with lipids and promoting virus infection and fusion (Gianni et al., 2006a).  
KSHV gL is required for the proper processing and transport of KSHV gH to the infected 
cell membranes.  Anti-gH and anti-gL rabbit antibodies neutralized KSHV infectivity without 
inhibiting the binding of virus to target cells, suggesting that gH and gL play an important role in 
the post-binding step of KSHV infection.  KSHV gH and gL expression can be easily detected 
during lytic replication induced by TPA in BCBL-1 cells (Naranatt, Akula, and Chandran, 2002).  
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KSHV-gL is independently expressed on cell surfaces.  However, independent expression of gH 
without gL causes gH mis-folding and aggregation of gH in the ER.  In contrast, co-expression 
of KSHV gH with gL facilitates the correct processing of gH and mediates transport through the 
Golgi apparatus with subsequent cell surface expression (Naranatt, Akula, and Chandran, 2002).  
Antibodies against either gH or gL do not inhibit KSHV binding, while anti-gH and anti-gL 
antibodies do neutralize KSHV infectivity at a post-attachment step of HHV-8 infection 
(Naranatt, Akula, and Chandran, 2002). 
Glycoprotein M (gM) and Glycoprotein  (g) 
The KSHV-ORF39 and KSHV-ORF53 encode gM and gN, respectively.  The gM and gN are 
conserved throughout the entire family of Herpesviridae.  Immunoprecipitation experiments have 
shown that both KSHV-gM and gN are N-glycosylated and form heterodimers.  The 
heterodimers formation between gM and gN is similar to the heteroduplex formation in other 
herpesviruses (Jons, Dijkstra, and Mettenleiter, 1998; Lake, Molesworth, and Hutt-Fletcher, 
1998; Mach et al., 2000; Rudolph et al., 2002; Tischer et al., 2002; Wu, Zhu, and Letchworth, 
1998).  The glycosylated forms of gM are observed at 46kDa and 80kDa.  The molecular sizes 
are reduced to 39kDa and 71kDa with the addition of tunicamycin (an inhibitor of N-
glycosylation).  The glycosylated form of gN is approximately 26kDa and upon tunicamycin 
treatment the unglycosylated form is approximately 18kDa. gN has shown to be required for 
proper post-translational modification and transport of gM to the cell surface (Koyano et al., 
2003).  In addition, gM was present on the surface of the virion envelope as indicated by an anti-
peptide antibody directed against gM reacted with double-purified sucrose gradient 
centrifugations (Koyano et al., 2003).  The KSHV gM and -gN heterocomplex was shown to 
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inhibit cell fusion in an in vitro cell fusion assay of HSV-1 and Mo-MuLV (Molony murine 
leukemia virus) (Koyano et al., 2003). 
Glycoprotein OX2 (vOX2) 
Viral genomic analysis of KSHV suggests that ORF K14 possesses a significant level of 
homology with cellular OX2, currently designated as viral OX2 (vOX2).  Cellular OX2 belongs 
to a group of leukocyte glycoproteins which are expressed on the surface of a myriad of cells: 
activated T cells, B cells, follicular dendritic cells, neurons, and vascular endothelial cells 
(Wright et al., 2003; Wright et al., 2000).  The respective receptor for CD200 is CD200R, which 
has been primarily found mainly on cells of myeloid origin (Wright et al., 2000; Wright et al., 
2003).  A study has indicated that the immunosuppressive effect of CD200/CD200R interaction 
may be associated with T-cell; since the receptor CD200R is also present on the surface of 
certain T-cells (Wright et al., 2003).  CD200 possesses a small carboxyl-tail without noticeable 
signal transduction motifs.  However, the CD200R possesses a large cytoplasmic tail with 
tyrosine-based signaling motifs, which potentially could be used to deliver its restrictive 
immunological effect on myeloid cells (Wright et al., 2003).  The KSHV ORFK14 encodes the 
vOX2 specifying 271 amino acids, which is similar to both cellular OX2 (278 a.a) and RRV R14 
(253 a.a) (Alexander et al., 2000; Searles et al., 1999).  
The predicted KSHV vOX2 contains a typical signal peptide sequence at its amino-
terminal region and five potential N-glycosylation sites in its extracellular domain.  ORFK 14 
(vOX2) exhibits a low 40% DNA sequence identity to cellular OX2.  vOX2 binds to the receptor 
CD200R with almost identical affinity and kinetics as the cellular OX2 (Chung et al., 2002).  
The c-OX2-OX2R interaction delivers a restrictive signal to macrophages thus limiting 
macrophage activation.  Subsequently, blocking of this interaction with anti-OX2R antibody 
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exacerbates tissue damage in inflammatory sites (Wright et al., 2000).  CD200R on the surface of 
macrophages can interact with vOX2 expressed on the surface of lytic KSHV-infected cells.  It 
has also shown that the KSHV vOX2 can inhibit the TNF-α secretion from activated 
macrophages via CD200R-vOX2 interaction (Foster-Cuevas et al., 2004).  
vOX2 encodes a glycosylated protein with an apparent molecular mass of 55 kDa, is 
expressed on the surface of KSHV-infected cells during viral lytic replication and specifically 
recognizes myeloid-lineage cells (Chung et al., 2002).  Viral homologs to CD200 span large 
taxonomical gaps, including betaherpesvirinae (HHV-6) (Gompels et al., 1995) and HHV-7 
(Muralidhar et al., 2000); Gammaherpesvirinae (rhesus macaque rhadinovirus) (Desrosiers et al., 
1997; Searles et al., 1999) and KSHV (Chang et al., 1994); along with numerous viruses within 
the Pox family (Cameron et al., 1999; Lee, Essani, and Smith, 2001; Willer, McFadden, and 
Evans, 1999).  These evidences suggest a common viral immunoevasion strategy which 
negatively restricts activated macrophages, thus potentially providing an explanation for KS 
sarcomagenesis (Chung et al., 2002; Foster-Cuevas et al., 2004).  vOX2 fused with the Fc 
domain of human immunoglobulin G1 has been reported to inhibit neutrophil oxidative burst and 
inhibited the production of pro-inflammatory chemokines (IL-8 and monocyte chemo-attractant 
protein 1) by monocytes/macrophages.  Therefore, vOX2 may be associated with immune 
dysfunction and could have anti-inflammatory therapeutic potential (Rezaee et al., 2005).  
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CHAPTER II 
MOLECULAR DETERMIATS OF KSHV TUMORIGEICITY 
ITRODUCTIO 
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), 
was first discovered in 1994 in Kaposi’s sarcoma (KS) tumors of AIDS patients.  KSHV is a 
member of the gamma-2-herpesvirus family (genus Rhadinovirus) (Neipel et al., 1997; Russo et 
al., 1996) and associated with the development of Kaposi’s sarcoma, primary effusion lymphoma 
(PEL) or body cavity-based lymphoma (BCBL), and multicentric Castleman’s disease (Antman 
and Chang, 2000; Ganem, 1998; Schulz, 1998a; Schulz, Sheldon, and Greensill, 2002).  KSHV 
infects many human cell types; furthermore, KSHV has a number of oncogenes which alter 
target cell functions.  Envelope-associated glycoprotein B gene is encoded by one of these 
oncogenes and is the focus of this chapter (Sarid et al., 1998). 
Herpesviruses, as a general rule, initiate viral attachment to the cell surface by binding to 
ubiquitous glycosaminoglycans, such as heparan sulfate-like (HS-like) molecules.  This 
attachment is mediated by several envelope-associated glycoproteins.  Earlier studies have 
shown that KSHV binds to host cell HS-like receptors via the K8.1 protein and the RGD motif of 
gB.  In contrast to the gB protein of EBV, KSHV gB is expressed on the surface of the cells and 
on the virion envelope (Akula et al., 2001a; Pertel, 2002; Wang et al., 2003).  In addition, a 
recent study indicates that gB can regulate many cellular signaling pathways and facilitate virus 
penetration into host cells by specifically binding to the α5β3 integrin through an RGD (Arg-
Gly-Asp) motif.  gB-mediated signaling pathways and cytoskeletal remodeling play important 
roles in the development of tumors (Sharma-Walia et al., 2004).  Viral glycoprotein B is also 
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important in the fusion of the KSHV viral envelope with either cellular or endosomal 
membranes, as well as virion morphogenesis and egress (Birkmann et al., 2001). 
The mechanisms of KSHV pathogenesis and tumorigenesis have not been fully 
elucidated due to the lack of appropriate animal models susceptible to KSHV infection.  Since 
KSHV can only replicate in human cells, severe combined immunodeficient (SCID) mice have 
been engrafted with normal human tissue and subsequently injected with purified KSHV virions 
(Dittmer et al., 1999; Foreman et al., 2001; Picchio et al., 1997).  Alternatively, KSHV-infected 
human tumor cells, such as PEL, have also been injected into SCID or nude mice (Komanduri et 
al., 1996; Salahuddin and Markham, 1988; Zenger et al., 2002).  Mice injected with the cell-free 
KSHV virus did not develop tumors or clinical symptoms.  However, ascites tumors were 
observed in SCID mice injected with KSHV-positive BCBL-1 cells.  Studies on different BCBL-
1 cell injection sites have suggested that intraperitoneal or subcutaneous injections of the PEL 
cell line in mice cause them to develop ascites or solid tumors (Picchio et. al., 1997).  Moreover, 
the extracellular matrix is important for the development of tumors, and Matrigel matrix 
(solubilized basement membrane) is believed to facilitate PEL tumor growth (Staudt et al., 
2004).  A recent study shows that primary effusion lymphomas in NOD/SCID mice are inhibited 
by a combination of azidothymidine and interferon-alpha (Wu et al., 2005).  Long-term-infected 
telomerase-immortalized endothelial (TIVE) cells have been successfully developed as a model 
for evaluation of KSHV latency in vitro and in vivo (Grisotto et al., 2006).   
Stable 100% KSHV infected PEL cell lines are the most consistent model to study KSHV 
gene expression and function as well as the effects of infection.  Many previous studies of human 
cancer cell types have suggested that the implantation of cells in nude mice have similar 
biological behaviors to these cancer cells in humans.  An effective example of this is human 
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prostate cancer cells which form primary tumors but metastasize inefficiently when implanted in 
nude mice. 
The overall objective of this study was to develop an animal model that could be used to 
assess the potential molecular determinants of KSHV tumorigenicity in vivo.  RNA interference 
has been used as a powerful tool for silencing the function of specific genes (Arens et al., 2005; 
D'Alessio et al., 2004; Schweinitz et al., 2004).  siRNAs provide a great potential strategy not 
only for the examination of gene function but also for the development of gene-specific 
therapeutic modalities (Gondi et al., 2003; Jiang, Rubbi, and Milner, 2004; Miyagishi and Taira, 
2003).  Previous studies in our laboratory have shown that the KSHV gB is important in virion 
egress from BCBL-1 cells.  With this in mind, we injected PEL or BCBL-1 cells transfected with 
plasmid vectors expressing anti-gB siRNA and codon-optimized gB that cannot be recognized by 
anti-gB siRNAs in the presence of Matrigel subcutaneously in nude mice.  Tumors treated with 
anti-gB siRNAs were significantly smaller than those in codon-optimized gB and negative 
control groups. The results of this study indicate that gB plays important roles in KSHV-induced 
tumorigenicity.  
MATERIALS AD METHODS 
Cells and Viruses Propagation 
The BCBL-1 cells harboring the rKSHV.152 genome constitutively expressing the green 
fluorescent protein (gift from Dr. Vieiria) were routinely grown in RPMI 1640 medium 
(HYCLONE) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (HYCLONE), 
2mM glutamine, 1% penicillin/streptomycin (pen/strep) (GIBCO) and 250 mg of G418/ml 
(GIBCO).  The rKSHV.152 contained the green fluorescence protein (GFP) gene cassette under 
the human cytomegalovirus (CMV) immediate-early promoter, constitutively expressing the 
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GFP gene.  293 A cells (American Type Culture Collection, ATCC) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; GIBCO) with 10% FBS, 2 mM L-glutamine and 1% 
pen/strep.  Cell cultures were maintained at 37ºC in a humidified atmosphere of 5% CO2.  The 
KSHV lytic cycle was induced in the BCBL-1 cells by adding 25 ng/ml of 12-O-
tetracanoylphorbol-13-acetate (TPA, Sigma, St. Louis, Missouri).  Virus from the supernatant 
was collected after 16 hours and treated with DNase I before extraction of viral DNA as 
described previously (Luna et al., 2004).  The supernatants were collected 48 hours post 
induction with TPA for infectivity studies.   
Antibodies  
Rabbit polyclonal antibodies generated in our laboratory against KSHV gB peptides were used to 
detect gB protein in western blot analysis as described previously (Baghian et al., 2000).  The 16 
peptide antibodies specific to 167-191 amino acids (a.a) of the gB protein were used in this 
study.  Mouse anti-Hu GAPDH monoclonal antibodies were used to detect the GAPDH.  Other 
antibodies were used in this study including rat polyclonal antibodies to LANA, mouse 
monoclonal antibodies to K8.1, mouse monoclonal antibodies to ORF 59 (Advanced 
Biotechnologies, Inc., Columbia, Md).  
Vectors Construction  
The siRNAs were constructed to target the 5’ region of KSHV gB expression sequence.  This 
construction was accomplished using AMBION’s online siRNA Target Finder.  The siRNA 18 
was located from the nucleotide 403 after the ATG codon, while siRNA 22 located starting at 
484 bases from the ATG codon.  Two siRNAs specifically selected against gB were generated as 
follows: si18 (sense strand HindIII---5`AGCTTCAAGTATGAACTCCCGAGATTCAAGAGA 
TCTCGGGAGTTCATACTTGTTG-3`; anti-sense strand-EcoRI--5'AATTCAACAAGTATG 
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AACTCCCGAGATCTCTTGAATCTCGGGAGTTCATACTTGA-3'); si22 (sense strand-
HindIII—5'AGCTTGGTAAATGTCAACGGGGGTATTCAAGAGATACCCCGTTGACATTT 
ACCTTG-3'; anti-sense strand-EcoRI---5'AATTCAGGTAAATGTCAACGGGGTATCTCTT 
GAATACCCCGTTGACATTTACCA-3').  The siRNAs oligonucleotides containing HindIII and 
EcoRI were designed to carry the HindIII and EcoRI overhangs at the 5’ and 3’ ends, 
respectively.   
The siRNA 18 and siRNA 22 were denatured at 94 ºC for 5 minutes and cool down slowly 
to room temperature allowing for annealing of the two strands.  Each annealed siRNAs was 
cloned into the HindIII / EcoRI digested p3xFLAG vector by T4 DNA ligase (NEB).  The 
ligation mixture was transformed into One Shot TOP10 chemically competent E. coli cells 
(Invitrogen) and spread on LB agar plate containing 100ug/ml ampicillin.  All recombinant 
constructs were confirmed by further restriction enzymes digestion and sequenced to their 
structure.  
Codon Optimization 
The codon optimization of the first 540 bases of KSHV gB, from ATG to the HpaI restriction 
site, were accomplished by using the DNAWorks Web Site: 
http://molbio.info.nih.gov/dnaworks.  This codon-optimized fragment was designed to replace 
the first 540 bp region of WT KSHV gB carrying siRNA’s targeting sequences between the KpnI 
and HpaI sites.  The codon-optimized gB was cloned in the expression vector p3xFLAG between 
the KpnI and BamHI sites.  The wild type KSHV gB was cloned in the expression vector 
p3xFLAG within the KpnI and BamHI sites.  A 577bp ECMV internal ribosome entry site 
(IRES) was amplified from pIRESHyg3 vector (Clontech) by using the primers indicated in 
Table 1.  The recovered IRES fragment inserted between the BglII and EcoRV restrictions sites 
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was placed downstream of the siRNA and upstream of codon-optimized gB in the p3xFLAG 
vector.   
Transient Transfection of BCBL-1 Cells 
Transient transfection of BCBL-1 cells was carried out using Superfect (Qiagen) transfection 
agent according to the manufactuere’s instructions.  BCBL-1 cells were counted, followed by 3 
washes in phosphate-buffered saline (PBS). 0.5 x 10
5
/well cells were plated in 12-well plates.  
Cells were transfected with plasmids containing si18 IRES and si22 IRES together, p3xFLAG 
vector (negative control plasmid), and codon-optimized gB siRNA IRES mixed with Superfect 
in PRMI 1640 as recommended by the manufacturer.  All transfections contained the same 
amount of total transfected DNA.  After 4 h of incubation at 37 ºC, fresh PRMI 1640 with 10 % 
fetal bovine serum was added.  
Tumor Formation 
Cells were counted, washed once in ice-cold PBS, and diluted in cold phenol red-free Matrigel 
(BD biosciences discovery labware).  Female athymic nude mice (4 weeks of age; Charles River 
Laboratories) were housed in autoclaved cages with high-efficiency filter tops and autoclaved 
bedding.  The animal room was kept at 25 ºC with a 12-hr-dark cycle.  At 6-7 weeks of age, the 
nude mice (n=10/group, 19-21g body weight) were injected subcutaneously with 5 x 10
6
 
transient transfected BCBL-1 cells containing 200 ul Matrigel.  The mice were then observed 
every day for palpable tumors.  Body weights were determined weekly, and tumor size was 
measured.  Measurements were taken after 7 days of tumor inoculation using a digital 
microcaliper.  Tumor volumes were calculated twice a week according to the following formula: 
volume = (length x width x height)/2.  Subcutaneous masses with the overlying skin as well as 
the spleen, liver, kidney, heart, and lung removed from the nude mice were fixed in 10% neutral 
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formalin and stained with Hematoxylin and Eosin (H&E) stain (Vector Laboratories).  Unstained 
slides from the above subcutaneous masses were routinely analyzed by using 
immunofluorescence assays.   
The animal studies were approved by the Institution Animal Care and Use Committee 
(IACUC) of Louisiana State University (Baton Rouge).  Animal care was in compliance with the 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Research, 
1996). 
In vivo Imaging 
Mice were anesthetized through the use of intraperitoneal injections of Avertin (2-2-2 
Tribromoethanol) at 0.2-0.4 mg/g.  Three min after Avertin taking effect, the mice were 
transported and imaged for 5-7 min using KODAK In-Vivo Imaging System FX Pro (Carestream 
health).  This system provides molecular signal localization in live animals. 
Viral DA Preparation 
Tumors from mice were prepared in PBS and homogenized manually with an all-glass Potter 
Elvehiem homogenizer (KIMBLE / KONTES.).  TurboDNase I (Ambion) were used to treat 200 
ml of the tumor homogenates for 2 hours at 37 ºC to ensure that nonencapsidated genomes were 
absent.  In these experiments, 1 U of TurboDNase I was used per 100 ul of sample.  Viral DNA 
from tumor homogenates was extracted by using the DNeasy blood and tissue Kit (Qiagen) as 
the manufacturer’s instructions. 
Immunofluorescence Assay 
Antigen retrieval was done by microwaving tissue in 1.5% antigen unmasking solution (Vector 
Laboratories) for 20 min at 60 ºC and cooling at room temperature for 20 min.  The 4µm sections 
from formalin-fixed and paraffin-embedded tumor tissues were washed with 1x PBS (phosphate 
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buffered saline) and 1x PBS containing 0.1% gelatin from cold water fish skin (FSG) (Sigma-
Aldrich) for 10 min, respectively.  The tumor sections were blocked by 10% mouse serum for 15 
min followed by 200 ul of DakoCytomation protein-block-serum-free solution 
(DakoCytomation) of each slide for 15 min at room temperature.  The sections were first stained 
with rat polyclonal antibodies to LANA, mouse monoclonal antibodies to K8.1, mouse 
monoclonal antibodies to ORF59 (Advanced Biotechnologies) at 1:100 dilution and rabbit anti-
gB polyclonal antibodies at 1:500 dilution for 1 h at room temperature in the humidity box.  
Slides were washed with 1x PBS/FSG for 10 min and then incubated with AlexaFluor 488-
labeled goat anti-rat IgG, AlexaFluor 488-labeled goat anti-mouse IgG, or AlexaFluor 488-
labeled goat anti-rabbit IgG (Invitrogen) for 30 min at room temperature in the humidity box.  
All AlexaFluor 488-labled goat IgGs were filtered with 0.2um PES w/GMF (Whatman) filters 
before being applied to slides.  All the slides were washed once with 1x PBS and the nuclei were 
stained by incubation with 1ug/ml of DAPI (Invitrogen) for 30 min at room temperature.  Slides 
covered with cover-slips were washed once with 1x PBS and observed using fluorescence 
microscopy.  
BCBL-1 Cells Proliferation Rate Assay 
The in vitro cell proliferation rate of transiently transfected and non-transfected GFP-positive 
BCBL-1 cells was determined by plating BCBL-1 cells (in triplicate) with and without Matrigel 
in the wells of 96-well plates.  BCBL-1 cells were transfected with plasmids containing siRNAs, 
siRNA-codon-optimized gB and empty vector p3xFlag.  Transfected and non-transfected GFP-
positive BCBL-1 cells plated in the absence of Matrigel in the other 96-well plate were used as 
controls.  Cells were harvested and counted using a hemocytometer from day 1 to day 7. 
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Statistical Analysis 
The SAS® (Version 9.1.3) GLM procedure was used to analyze the data of tumor volumes in an 
analysis of variance of a split-plot arrangement.  Statistical analyses using this model included 
the treatment group and the group of untreated animals as main plot effects, and the Period and 
Treatment Group by Period interaction as subplot effects.  When overall F tests indicated 
significance, post hoc pairwise comparisons of main effects were conducted with Turkey’s HSD 
test.  Pairwise comparisons of significant interaction effects were made with t tests of least-
square means.  All comparisons were considered significant at P≤0.05. 
Table2.1: Synthetic Oligonucleotide Primers 
PRIMER NAME SEQUENCE 5`-3` 
Ires For.  agatctcactagaggaattccg  
Ires Rev. gatatcgtggcaagcttatcatc  
gB Universal For tccagactacccacgaggac 
gB Universal Rev gtcaggttaatcgcggacat 
gB WT For gacacctttcagacgt  
gB WT Rev tctcgggagttcatacttgt  
Orf 59 Pro FAM cgcgtgagctattcggtgcgaata TAMRA 
Orf 59 For tcagcttcaggaatacgtccg 
Orf 59 Rev ggctatgccagcgtcgagta 
GAPDH For gattccacccatggcaaatt  
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RESULTS 
Construction and Characteristics of Expression Plasmids 
To study the role of glycoprotein B in KSHV virus egress and tumor progression, we used 
siRNAs to knockdown gB gene expression in BCBL-1 or PEL cells.  gB expression has been 
linked to virus-induced cell fusion as well as entry.  First, we developed p3xFlag-CMV plasmid 
vectors containing the wild-type (WT) gB genes and codon-optimized gB.  The corresponding 
WT region, from ATG to the HpaI site of the codon-optimized gB, was replaced with a 540 base 
fragment amplified by a set of 22 overlapping primers.  siRNAs-IRES driven by human CMV 
promoter, were cloned by inserting siRNAs between the HindIII and EcoRI sites followed by an 
IRES fragment.  The 577 bp internal ribosome entry site (IRES) of the encephalomyocarditis 
virus (ECMV) was amplified from pIRESHyg3 vector, which allows the expression of multiple 
proteins from one transcriptional mRNA.  The consistent expression of siRNAs targeted gB at 
the positions of 403 bp and 483 bp respectively.  siRNAs-IRES-codon-optimized gBs were 
constructed by inserting the IRES fragment downstream from between siRNAs and codon-
optimized gB sequentially into the p3xFlag-CMV vector.  Next, siRNAs-IRES plasmids and 
siRNAs-IRES-codon-optimized gBs were transfected in the 293 cells and BCBL-1 cells.  BCBL-
1 cells transfected with Superfect, wide type gB and non-specific siRNAs were used as controls.  
Transient Expression of gB In 293 Cells  
As shown in Figure 2.3, analysis of the siRNA-transfected 293 cells for gB gene expression via 
reverse transcription-PCR demonstrated a significant reduction in mRNA levels of gB in 293 
cells.  However, gB expression was recovered in siRNA-IRES-codon-optimized gB transfected 
cells.  In contrast, there was no dramatic inhibition of gB expression in 293 cells alone, 
Superfect-transfected 293 cells, wide type gB-expressing vector transfected 293 cells, or non-
- 93 - 
specific siRNAs plasmid transfected 293 cells.  Western blot analysis of cell debris showed that 
decreased gB protein production (as indicated in Figure 2.3) was associated with decreased 
mRNA gB expression.  Similarly, no effects of inhibition of siRNAs were observed on the 






Figure 2.1: Small Interfering RAs (siRAs) Selectively Block Expression of Genes.   
siRNAs binds to the RNAi silencing complex (RISC) which first mediates unwinding of siRNAs 
and binds to its target mRNA in a sequence specific way.  Codon-optimized gB can’t be 
degraded since the target sequence of siRNAs is replaced by the codon-optimized sequence.  
siRNAs oligonucleotides were synthesized to target WT gB at the positions 403 bp and 484 bp.  
     
Figure 2.2: Strategy Used to Construct the Codon-Optimized KSHV gB.  The codon-
optimized fragment amplified by PCR replaced the WT gB from the first 540 base pairs between 
the restriction sites KpnI and HpaI.  siRNA-IRES-codon-optimized gB was cloned into p3xFlag 
with siRNAs insertion between the HindIII site and EcoRI site followed by codon-optimized gB.  
The IRES gene was inserted at the restriction sites BglII and EcoRV between siRNAs and 
codon-optimized gB.  
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Figure 2.3: siRAs 18 and siRAs 22 Specifically Inhibit KSHV gB Expression in 293 
Cells.  Mock and 293 cells transfected with siRNAs and codon-optimized gB plasmids were 
examined by Reverse Transcription-PCR.  Total RNA was extracted from mock and 293 
transfected cells as described in materials and methods.  The GAPDH mRNA was also amplified 
as an internal control. Western blot of total protein extracted lysates was extracted from cell 
debris.  GAPDH was used as a loading control. siRNAs specifically down-regulated KSHV gB 
expression at both mRNA and protein levels. 
levels as well as protein levels.  These investigations clearly demonstrated the following:  Wide 
type gB effectively complimented codon-optimized gB in 293 cells.  More importantly, siRNAs 
18 and siRNAs 22 specifically inhibited KSHV gB expression. 
Transient Expression of gB In BCBL-1 Cells 
BCBL-1 or PEL cell lines have been shown to represent the most consistent model for studying 
KSHV gene expression and function in tumorigenicity.  KSHV expresses a small percentage of 
lytic infected cells while mainly expressing latent cells, which can be induced to become lytic 
with the 12-O-tetradecanoylphorbol 13-acetate (TPA).  Analysis of the effects of gene-specific 
siRNAs 18 and siRNAs 22 on KSHV gB expression in BCBL-1 cells used reverse transcription-
PCR.  Transient transfected BCBL-1 cells were induced by 25ng/ml TPA for 12 hours and 
RT-PCR Western blot 
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harvested.  Total soluble RNA was extracted from cellular debris treated with DNase I.  The 
mRNA level of WT gB expression was drastically reduced in siRNAs transfected BCBL-1 cells; 
while no significant inhibition of WT mRNA gB expression was observed in either siRNA-
IRES-codon-optimized gB transfected cells or control BCBL-1 cells.  Similarly again, reduced 
gB protein expression was correlated with siRNAs transfected cells in contrast to siRNA-IRES-
codon-optimized gB transfected or control BCBL-1 cells.  The expression of GAPDH was not 
inhibited by siRNAs, which was used as an internal control to normalize gB mRNA levels as 
well as protein levels.  Therefore, siRNAs 18 and siRNA 22 effectively silenced KSHV gB 
mRNA levels as well as protein expression in both the 293 cells and BCBL-1 cells.  
Quantification of KSHV by TaqMan PCR   
To better quantify the amount of virus produced by the transfection of BCBL-1 cells, a real-time 
PCR assay targeting ORF59 (a KSHV early lytic gene) was essential.  KSHV ORF59 encodes a 
viral DNA polymerase processivity factor involved in viral DNA replication.  Viral DNA was 
extracted using DNeasy tissue and Blood kit in the above supernatants of transfected BCBL-1 
cells.  KSHV DNA was generated based on known amounts of BAC36 DNA containing the WT 
KSHV genome.  The concentration of purified BAC36 DNA was determined by measuring 
optical density at 260 nm and by comparative gel electrophoresis using known amounts of 
molecular markers.  A standard curve based on the Ct value and logarithmic amounts of diluted 
BAC36 was constructed by diluting BAC36 DNA at serial 10-fold levels.  The Ct value was 
identified as the cycle number at which fluorescence detection exceeded an established constant 
threshold level among all the experiments.  
As shown in Figure 2.5, siRNA 18- and siRNA 22- transfected BCBL-1 cells produced 
relatively large numbers of KSHV genomes in supernatants, with a little higher amount of viral  
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genomes produced in the siRNA 18 group.  BCBL-1 cells alone or transfected with Superfect 
produced about two-fold more viral KSHV genome than cells transfected with siRNAs18 and 
 
 
Figure 2.4: siRAs 18 and siRAs 22 Specifically Inhibit KSHV gB Expression in BCBL-1 
Cells.  Reverse Transcription-PCR was used to examine gB expression in mock and BCBL-1 
cells transfected with siRNAs and codon-optimized gB plasmids.  Total RNA was extracted from 
mock and transiently transfected BCBL-1 cells as described in materials and methods.  The 
GAPDH mRNA was an internal control.  Western blot of total protein extracted lysates was 
extracted from cell debris.  The GAPDH protein was used as a loading control.  siRNAs 
specifically inhibited KSHV gB expression at both mRNA and protein levels in  BCBL-1 cells. 
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Figure 2.5: Reduced KSHV Genomes in Supernatants from BCBL-1 Cells Transfected with 
siRAs Determined by Quantitative Real-time PCR.  Supernatants were treated with DNase I 
to remove nonencapsidated genomes. Viral DNA and real-time PCR used the supernatants from 
cells transfected with plasmids containing siRNAs and siRNAs-IRES-codon-optimization gB.  
Supernatants from cells transfected with non-specific siRNAs, Superfect and mock cells were 
used as controls.  Error bars indicate standard deviations.   
siRNAs 22.  This effect of inhibition was siRNAs specific, since transfection of non-specific 
siRNAs did not down-regulate the expression of viral genomes found in supernatants. 
Codon-optimization has been indicated as a powerful tool for enhancing protein 
expression by altering gene sequences from small RNA and DNA viruses (Bradel-Tretheway, 
Zhen, and Dewhurst, 2003; Villalobos et al., 2006).  Hence, the number of KSHV genomes 
found in supernatants of codon-optimized gB transfected BCBL-1 cells were a little higher than 
in Superfect, non-specific siRNAs transfected and negative control BCBL-1 cells; this may be 
due to the codon optimization in the gB gene sequence.  Transfection of siRNAs 18-codon-
optimized plasmid yielded approximately three fold more viral genomes in BCBL-1 cells 
compared to those found in siRNAs transfected BCBL-1 cells.  
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Characteristics of PELs in ude Mice   
In our studies, BCBL-1 cells were transiently transfected with the same plasmids as mentioned 
above.  Female athymic nude mice (nu/nu; n=10/group) were injected subcutaneously in the 
interscapular area with 5x10
6 
transiently transfected BCBL-1 cells mixed with Matrigel.  Tumor 
incidence and tumor volume were recorded twice a week until sacrifice.  Mice weight was 
measured once a week.  The palpable tumor was typically observed 7 and 14 days after tumor 
inoculation.  When the tumor growth was detectable, the tumor volume (mm
3
) was measured 
every 3-4 days.  Representative figures of tumors in mice injected with transfected BCBL-1 cells 
are presented in Figure 2.6. 
 
Figure 2.6: A Representative Subcutaneous Mass before and after Dissection.  A.  Mouse 
showing subcutaneous PEL tumor in the presence of Matrigel four weeks after inoculation.  B. 
Appearance of PEL tumor in Matrigel after dissection of the skin (the red circle).   
 
In Vivo Imaging of PEL Tumors 
As shown in Figure 2.7, BCBL-1 cells constitutively expressed the GFP gene, allowing for 
detection of tumor progression and eukaryotic cells containing KSHV genomes under 
fluorescence microscopy.  Constitutive expression of GFP was produced by the KSHV genomes 
that containing green fluorescence protein (GFP) gene cassette driven by the human 
cytomegalovirus (CMV) immediate-early promoter.  KSHV is essential for the development of 
primary effusion lymphomas.  In order to localize KSHV genomes in subcutaneous tumors in 
live mice, we use X-ray and fluorescence to image living nude mice.  This is an example of the 
A B 
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tumor in nude mice which contains the GFP-positive tumor by X-ray and florescence as shown 
by Figure 2.7.  
                               
Proliferation of BCBL-1 Cells In Vitro with Matrigel 
The RGD motif of gB is important for cell attachment via the interaction between cell surface 
molecules and integrins.  In addition, the RGD sequence participates in vascular development 
and remodeling mediated by binding to extracellular matrix (ECM) proteins and endothelial 
cells.  Transiently transfected BCBL-1 cells were plated in 96-well plates in either the presence 
or absence of Matrigel.  Cell numbers were counted every day, from day 1 to day 6.  As shown 
in Figure 2.8B, GFP expressing BCBL-1 cells tend to grow together in the center of wells in 
contrast to the distinct distribution of individual cells in the matrigel.  In the absence of matrigel, 
BCBL-1 cells transfected with plasmids containing siRNAs, siRNAs-IRES-codon-optimized gB 
and negative control p3xFlag vectors grew faster higher than cells supported by Matrigel (graph).  
No significant differences were observed among different groups of BCBL-1 cells.   
 
 
Figure 2.7: X-ray and Fluorescent 
Image of ude Mouse .  GFP-
expressing BCBL-1 cells were 
injected into the interscapular area of 
nude mice. Mice were anesthetized 
with Avertin i.p. and images were 
taken by using KODAK In-Vivo 
Imaging System FX Pro. Detection of 
green fluorescence from GFP gene in 
cells indicated KSHV genomes in 
PEL tumors.    
 












Figure 2.8: In Vitro GFP+ BCBL-1 Cells Proliferation Rate with matrigel.  Cells were 
counted every day by using hemocytometer.  GFP expressing BCBL-1 cells in the absence of 
Matrigel were tended to grow together in the center of the well.  In contrast, in the presence of 
Matrigel, cells grew separately.  All images were at x50 magnification level. 
PEL Tumor Growth  
Subcutaneous masses developed in nude mice injected with siRNAs transfected BCBL-1 cells 
produced a highly significantly smaller size of tumors (P< 0.0001) in comparison with controls 
of codon-optimized, negative control p3xFlag vectors and mock cells alone 17 days after 
inoculation (Figure 2.9).  Tumors with Matrigel formed in nude mice injected with codon-
optimized transfected PEL cells showed no significant difference from those obtained from non- 
transfected BCBL-1 cells with slightly larger tumor volumes.  Statistical analysis indicated that 
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tumors injected with negative control p3xFlag vectors were significantly different from that 
injected with codon-optimized, siRNAs transfected or non-transfected mock cells (p<0.0001).  
From day 7 to 30 after inoculation, tumors in mice injected with codon-optimized, p3xFlag 
vectors and BCBL-1 cells were not significantly different within the same periods as indicated 
by the overlapped bars.  Correlation analysis of mice weight and tumor growth demonstrated that  
 
Figure 2.9: Effect of Transfected BCBL-1 Cells in ude Mice.  Primary effusion lymphomas 
were established by injecting subcutaneously mock-transfected and transfected BCBL-1 cells 
with various plasmids in the presence of Matrigel into the interscapular areas of nude mice.  
Tumor volumes were recorded with a digital caliper every 3-4 days (x axis).  BCBL-1 cells were 
transiently transfected with plasmids harboring siRNAs-IRES, siRNAs-IRES-codon-optimized 
gB and p3xFlag vector (negative control).  “0” indicates the first day of injection.  Tumor 
volumes were estimated according to the formula: volume = (length x width x height)/2.  All 
results at each time points are presented as means + standard errors.  Overlapped standard error 
bars indicated a not significant difference among different groups.  
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tumor growth was not affected by different weight gain/loss in all four study groups of nude 
mice injected with cells transfected different plasmids (data not shown).  
Pathobiological Examination of Tumors  
Neoplastic cells were observed within the subcutaneous masses; however, there was no evidence 
of metastasis in spleen, liver, kidney, heart, or lung.  No overt histological difference was present 
in the subcutaneous masses among the groups.  The masses were composed of multiple islands 
and/or sheets of round to polygonal neoplastic cells admixed with abundant eosinophilic 
homogeneous material (Matrigel) (Figure 2.10A).  The sheets of neoplastic cells were mostly 
present at the periphery of the masses.  The neoplastic cells were shown to have a round to 
irregular shaped nuclei with small to moderate amount of cytoplasm (Figure 2.10B).  Based on 
the nuclear morphology, the neoplastic cells were separated to three types: 1. lymphoblastic cell 
type characterized by a large irregular shaped hyperchromatic nucleus with an obscured nucleoli; 
2. immunoblastic cell type characterized by a large irregular shaped nucleus with single or 
multiple prominent nucleoli; 3. small lymphocytic cell type characterized by a small round 
hyperchromatic nucleus with an obscured nucleolus.  Each neoplasm consisted of single or 
mixed cell types described above.  The mitotic rate was 0 to 15 per high power field (x400), and 
there were occasional binucleated cells.  Occasionally, neoplastic cells were separated by clear 
spaces, which were most consistent with an artifact during the process of sectioning.  Multifocal 
necrosis was present within all masses except one injected BCBL cells.  There were rare 
infiltrates of macrophages.  All masses contained small numbers of blood vessels, which were 
lined by plump endothelial cells and contained erythrocytes (Figure 2.10B), and/or spindle cells 
interpreted as endothelial cells forming capillaries or fibroblasts (Figure 2.10B inset). 
 
- 103 - 
 
Figure 2.10: Subcutaneous Masses Stained with Hematoxylin and Eosin (H&E).  (A) 
Multiple islands and sheets of neoplastic cells were observed within abundant eosinophilic 
homogeneous material (Matrigel) as well as multifocal necrotic areas. (B) Round to polygonal 
neoplastic cells had large irregular shaped nuclei containing occasional prominent nucleoli, with 
multiple mitotic figures (long white arrow).  A focal area of necrosis characterized by pyknotic 
nuclei and cellular debris was surrounded by short white arrows.  The blood vessel lined by 
plump endothelial cells and filled with erythrocytes was indicated by a black arrow.  Spindle 
cells within Matrigel were shown inset.   
Characterization of KSHV Infected PEL Tumor Cells  
Previous studies have indicated that the marker of KSHV latency, latent nuclear-associated 
(LANA) protein, is expressed in all the PEL or BCBL-1 cells in suspension culture.  To further 
determine the presence of KSHV in the GFP
+
 BCBL-1 cells of tumors; immunofluorescence was 
carried out to examine the expression of the LANA antigen of PEL tumors supported by 
Matrigel in mice.  As seen in Figure 2.11D, most of the tumor cells were positively stained for 
LANA in tumors derived from BCBL-1 cells.  The LANA antigen was detected as a classic 
nuclear punctuated pattern suggesting KSHV episomes in the host chromosome (Ballestas, 
Chatis, and Kaye, 1999) as shown in Figure 2.11E.  To further investigate the characterization of 
the KSHV-harboring BCBL-1 cells in tumors and the status of their KSHV infection, tumor cells 
were detected from the transient expression of gB and lytic genes K8.1 and ORF59 by indirect 
immunofluorescence.  Antibodies against glycoprotein B and late lytic antigen K8.1 stained cells  
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Figure 2.11: KSHV Lytic and Latent Gene Expression of in Matrigel-Supported BCBL-1 
Tumors.  (A) Tumor tissue was stained with anti-gB rabbit polyclonal antibodies and detected 
with AlexaFluor 488-conjugated anti-rabbit antibodies in the cell membranes.  (B) Tumor 
sections were stained with mouse monoclonal antibodies against the K8.1 protein and detected 
with AlexaFluor 488-conjugated anti-mouse antibodies in the cell membranes.  (C) The tumor 
was stained with a mouse monoclonal antibody against the lytic ORF 59 protein followed by 
secondary antibody, AlexaFluor 488-conjugated anti-mouse antibody.  (D) The tumor was 
stained with a rat polyclonal antibody against the LANA protein and detected with AlexaFluor 
488-conjugated anti-rat polyclonal antibodies.  (E) Nuclei were stained by DAPI.  DPAI is 
merged with the LANA protein which displays a punctuate pattern.  All images are at x 1000 
magnification.  
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were stained in their cell membranes (Figure 2.11 A and B).  ORF59 (DNA processivity factor) 
showed nuclear stain.  These results together showed that lytic reactivation from latently infected 
cells harboring KSHV occurred during the development of tumors. 
DISCUSSIO 
BCBL-1 cell lines harboring patient-derived KSHV have been demonstrated to be the most 
consistent model for investigating the structure and function of KSHV genes in both lytic and 
latent replication.  Furthermore, virtually all PEL cells express the viral latency-associated 
nuclear antigen LANA, v-Cyclin, and v-FLIP indicating that KSHV is required for tumorigenesis 
(Dupin et al., 1999; Fakhari and Dittmer, 2002; Sarid et al., 1998).   
 RNA interference has been used as a powerful tool for silencing the function of specific 
genes (Schweinitz et. al., 2004, Arens et. al., 2005, D’Alessio et. al., 2004).  Although 
conventional antisense technologies are sequence selective and provide very good alternatives to 
conventional gene deletion technologies, it is common for anti-sense RNA to only transiently 
and partially suppress the expression of the genes of interest (Gondi et. al., 2003, Arens et. al., 
2005, Miyagishi et. al., 2003).  siRNA provides a new and effective strategy not only for the 
examination of gene function but also for the development of gene-specific therapeutic 
candidates (Gondi et al., 2003; Jiang, Rubbi, and Milner, 2004; Miyagishi and Taira, 2003). 
The cloning of HHV-8 genome into bacterial artificial chromosome (BAC) allowed the 
rapid generation of KSHV mutant viruses (Gao, 2003; Zhou, 2002, Zhu 2006).  Mutated KSHV 
viruses have been constructed to investigate the function of KSHV genes essential for growth 
and replication in tissue culture.  However, these viral genomes, in most cases, could not lead to 
robust infection and production of relatively large numbers of infectious virions effectively 
limiting their use in investigating the structure and function of individual viral proteins. 
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In this study, anti-gB siRNAs were used to inhibit gB synthesis in BCBL-1 cells that 
produce large amounts of infectious virions upon the induction of lytic replication.  Co- 
transfection of BCBL-1 cells with anti-gB siRNAs and the codon-optimized gB, which is not 
susceptible to siRNA inhibition, effectively increased gB mRNA levels and gB expression.  In 
these experiments, the siRNAs were cloned in tandem with the codon-optimized gB to ensure the 
co-expression into the same transfected 293 and BCBL-1 cells.  gB mRNA expression and gB 
proteins was reduced by approximately 40-60% in the experiments of transient expression of 
either si18 or si22 in both 293 and BCBL-1 cells.  Therefore, a disproportionate number of 
BCBL-1 cells may be both transfected and reactivated if the transfection rate of BCBL-1 cells is 
not associated with lytic gene expression.  Recently, BCBL-1 cells in the S phase were shown to 
be more likely to undergo reactivation and display a smoother surface topology compared to 
those in G0/G1 phase (Whitman et al., 2007).  
 Studies have shown that gB may serve both conserved and different functions in gB-
mediated cell fusion, virion assembly, egress and infectivity among different herpesviruses.  
KSHV gB is essential for KSHV egress from 293 cells.  These results were obtained using a 
KSHV gB-null mutant obtained by insertion inactivation of the KSHV gB using a cloned KSHV 
genome as a bacterial artificial chromosome (Bac) plasmid (Krishnan et al., 2005) .  In this 
study, we showed that siRNA inhibition of gB synthesis led to drastic reduction in virion egress 
and infectivity in agreement with previous results indicating that gB is essential for virion egress 
and infectivity.  However, the cytoplasmic terminus of gB from amino acid residues 761 to 787 
is not essential for either virion egress or infectivity since gB truncations carrying this deletion 
did not affect virion egress and infectivity.  Therefore, these results suggest that KSHV gB 
domains other than the cytoplasmic domain are involved in virion egress and infectivity.  Lack of 
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gB caused the inhibition of virion egress while complementation of transient gB expression 
rescued KSHV virion egress from 293 cells.  It is possible that either or both the intramembrane 
and extra-cytoplasmic domains of gB directly or indirectly interact with some membrane bound 
proteins and glycoproteins associated with virion egress in the cytoplasm.  
 Our results demonstrated that anti-gB siRNAs quite effectively down-regulated the 
expression of KSHV gB mRNA as well as protein levels.  In order to gain a better understanding 
of the role of KSHV gB in tumorigenesis, we successfully established a mouse model using anti-
gB siRNAs-mediated silencing of gB system.  In nude mice subcutaneously injected with BCBL-
1 cells transiently transfected with anti-gB siRNAs, we found significant smaller tumors 
compared with mock- or only codon-optimized gB transfected cells.  Tumors growing from 
mock BCBL-1 in the presence of Matrigel were slightly smaller than those developed in codon-
optimized gB transiently transfected BCBL-1 cells supported by Matrigel.  This might be due to 
optimized codon usage that enhances KSHV gB gene expression.   
In summary, KSHV glycoprotein B can enhance virus egress from infected cells.  There 
is a slight difference of cell proliferation between transfected and non-transfected BCBL-1 cells 
in the Matrigel.  Statistical analysis of tumor volumes showed that tumors in nude mice injected 
with siRNAs-transfected BCBL-1 cells were significantly smaller compared to the tumors 
formed in the mice injected with siRNAs-IRES-codon-optimized gB, negative vector and mock 
cells.  Histological examination demonstrated multiple islands and periphery tumor masses, a 
number of blood vessels and spindle formation in the tumors with Matrigel.  However, 
differences of neither pathobiological morphologies nor angiogenesis in tumors among different 
experimental groups were observed.  Surprisingly, both latent and lytic genes were detected in 
tumors by immunofluorescence indicating that KSHV lytic infection may be important in PELs.  
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 What is the reason that tumors were reduced in siRNA-transfected BCBL-1 cells injected 
nude mice?  One possibility is that the production of infectious virus enhances tumorigenesis, 
possibly by direct infection of adjacent cells including endothelial cells that could enhance 
angiogenesis and other tumor-assisting functions.  Clinical studies show that KSHV lytic 
replication is critical for KS pathogenesis.  In order to expand a tumor mass, latently infected 
BCBL-1 cells injected into nude mice die and must be replaced by new latently infected cells.  
To provide such cells, endothelial cells infected with viruses produced by lytic replication 
become very important.  Another possible explanation is that lytic KSHV infected cells may 
produce some paracrine signaling molecules that lead to promotion in both the inflammation and 
angiogenesis of PEL tumors.  KSHV genome encodes a number of viral genes that produce 
signaling molecules homologous to cellular cytokines or chemokines.  Most of these genes are 
lytic genes, including viral CC chemokines vMIP, vIL-6, vGPCR (Aoki et al., 2001; Luttichau et 
al., 2000; Nador et al., 2001).  This study may provide new insights into the mechanisms of 
KSHV tumorigenesis. 
Angiogenesis is characterized by the formation of new blood vessels from pre-existing ones.  
Angiogenesis is a prerequisite for the growth and metastasis of many solid tumors.  
Angiogenesis is predominantly regulated by vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (b-FCG) released by tumor and/or stromal cells.  Angiogenesis 
plays important roles in pathogenesis of hematological malignancies.  It was shown that KSHV-
infected cells secrete VEGF and induce in vitro angiogenesis.  KSHV gB has been reported to 
facilitate KSHV infection and transformation via its interaction with VEGF receptor-3 (Zhang et 
al., 2005).  We also found that anti-gB inhibited the expression of VEGF in BCBL-1 cells 
transfected by anti-gB siRNAs in vitro (Subramanian, personal communication).  This may 
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suggest that anti-gB siRNAs inhibit the interaction between gB and VEGF resulting in the 
reduction of tumor size in nude mice injected with BCBL-1 cells transiently transfected plasmids 
coding for anti-gB siRNAs.  However, more experiments are needed in order to really 
understand gB functions.  
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CHAPTER III 
COLUDIG REMARKS  
FUTURE CHALLEGES 
KSHV gB is essential for virion egress in 293 cells (Krishnan et al., 2005).  Interestingly, we 
found that the carboxyl terminus of KSHV gB is not essential for virion egress and infectivity 
(Subramanian et al., 2008).  This work suggested that the intramembrane and/or extramembrane 
of gB may be important for virion egress.  Interestingly, HSV-1 gB is known to interact with at 
least two other viral glycoproteins, gH and gD and these interactions are important for HSV-1 
entry into cells and virus-induced cell fusion. Therefore, it is possible that gB interacts with other 
KSHV viral membrane proteins and glycoproteins that are important in virion egress.  
Determining the potential role of other KSHV viral glycoproteins and membrane proteins, as 
well as investigating potential interactions of gB with other viral proteins may shed more light 
into the regulation of virion egress from infected cells.  
Kaposi’s sarcoma is thought to be generated after KSHV infection of endothelial cells. 
Therefore, it is particularly important to investigate KSHV infection of endothelial cells. These 
studies are very difficult because KSHV does not efficiently infect endothelial cells. In contrast, 
BCBL-1 cells and other PEL cells produce large amounts of KSHV infectious virus and these 
cells can form tumors in immunocompromised mice.  Using Matrigel to enhance tumor 
development, anti-gB siRNAs transfected BCBL-1 cells inhibited tumor development in nude 
mice in comparison to codon-optimized gB, empty vector transfected BCBL-1 cells or alone.  
This result revealed that KSHV gB is important in the development of tumors.  BCBL-1 cells are 
latently infected and do not normally produce infectious KSHV unless they are stimulated by 
phorbol esters or other chemicals in cell culture. It is possible that a low level of KSHV-infected 
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BCBL-1 cells undergoes spontaneous lytic gene expression in vitro and in vivo, but this virus 
shedding a priori must not be required for tumor formation.  Therefore, it was surprising to find 
that BCBL-1 tumors implanted in nude mice appeared to efficiently activate KSHV’s lytic 
replication as evidenced by the expression of the lytic genes ORF59 and K8.1. Thus, it appears 
that some level of lytic replication may be important in tumor growth. Additional experiments 
are needed to clarify this issue.  
In our study, we successfully developed a siRNA-induced conditionally silencing system.  
This system allowed us to investigate the role of the carboxyl terminal region of KSHV gB in 
virion egress and infectivity and the role of gB in tumorigenicity.  However, transient 
transfection of siRNA in BCBL-1 and 293 cells in our previous studies provided only 10-15% 
transfection efficiency.  Moreover, transient expression cannot be maintained in dividing 
progeny cells.  Lentiviral RNAi mediated gene silencing system is one of the possible ways to 
promote transfection and transduction efficiency in vitro and in vivo.  Therefore, the next logical 
step of this line of investigation is to produce gB-null BCBL-1 cells by permanent expression of 
anti-gB siRNAs.  Establishment of these cells will be instrumental in dissecting the structure and 
function of KSHV gB in cell culture as well as in vivo animal model systems aimed at assessing 
potential functions of gB in virally-induced angiogenesis and tumorigenesis.  Currently, we are 
working on the establishment of the lentiviral RNAi system in BCBL-1 cells (Appendix).  
It is generally believed that tumor progression is highly dependent on angiogenesis.  
Vascular endothelial growth factor (VEGF) is currently thought to be one of the most important 
angiogenic factors involved in inducing the degradation of the vessel basement membrane, 
which in turn allows cells to invade the surrounding matrix.  It was shown that KSHV-infected 
cells secrete VEGF and induce in vitro angiogenesis.  KSHV gB facilitates virus infection and 
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transformation via its interaction with VEGFR-3 (Zhang, Groopman, and Wang, 2005; Zhang et 
al., 2005).  KSHV infected B cells can attach to extracellular matrix proteins via gB and cellular 
integrin in the presence of Matrigel (Dyson et al., 2008).  However, the pathways leading to the 
angiogenic factor secretion by PEL cells is not fully understood.  A number of previous studies 
showed that different factors may be responsible for the VEGF induction and its angiogenic 
effect.  vIL-6 was shown to promote stimulation of VEGF in vitro and in vivo (Aoki et al., 1999; 
Liu et al., 2001).  Raf was indicated to regulate the expression of a variety of growth factors 
including VEGF (Hamden et al., 2005).  KSHV K1 glycoprotein was also shown to up-regulate 
the expression by activating the VEGF promoter (Wang et al., 2004).  Very recently, VEGF and 
b-FGF secreted by PEL cells were found in the ascetic fluid of NOD/SCID mice (Haddad et al., 
2008).  Interestingly, preliminary studies in our laboratory have shown decreased expression 
levels of VEGF molecules in BCBL-1 cells transfected with anti-gB siRNAs (Subramanian, 
personal communication).  It would be important to determine the molecular basis of this 
phenomenon. 
SUMMARY 
KSHV glycoprotein B (gB) is one of the most conserved herpesvirus glycoproteins.  It is an 
essential virion component for members of alpha- and beta- herpesvirus subfamilies.  Envelope-
associated KSHV gB is important for viral attachment to cell-surface and virion entry via 
binding of the gB RGD to integrins.  Previous studies have shown that KSHV gB is essential for 
virion egress from 293 cells.  KSHV virus lacking gB was unable to egress from 293 cells.  In 
contrast, virion egress was detected in cells containing exogenously provided gB.  
I was fortunate to assist Dr. Ramesh Subramanian in delineating the role of the 
cytoplasmic terminus of gB in virion egress and infectivity.  This work showed that the carboxyl 
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terminus of gB is not important for either virion infectivity or egress from BCBL-1 cells 
(Subramanian et al., 2008).  I was able to show that BCBL-1 cells inhibited by anti-gB siRNAs 
were unable to develop continuously growing tumors in nude mice.  This is an important result 
that has to be further investigated in the immediate future.  It is highly probable that gB is 
directly involved in angiogenesis, since preliminary results in the laboratory appear to indicate 
that gB-inhibition down-regulates VGEF secretion from BCBL-1 cells (Subramanian, personal 
communication).  This result has to be confirmed in vitro and in vivo by following specific 
markers for angiogenesis. 
The production of BCBL-1 cells permanently transduced with siRNA cassettes through 
the use of the lentiviral vectors that have been already constructed will greatly facilitate future 
studies along the lines discussed above.  It is also possible that multiple KSHV genes can be 
simultaneously silenced to determine the combined effect of multiple glycoproteins and other 
viral genes that may be involved in tumorigenicity.  In this regard, the siRNA system may be 
proven to be a highly versatile system for the conditional silencing of multiple genes. 
Similar work with the BCBL-1 cells can be also performed to study Kaposi’s sarcoma 
(KS).  In this line of investigation KSHV infection of microvascular endothelial cells can be used 
in conjunction with nude or SCID mice to address the role of gB and other viral genes in 
Kaposi’s sarcoma induction. 
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APPEDIX 
GEERATIO OF STABLE KSHV GB-ULL CELL LIES 
Kaposi’s sarcoma-associated herpesvirus (KSHV) or the Human Herpesvirus-8 was first 
identified in 1994 (Chang et al., 1994).  KSHV is a member of the gamma-2-herpesvirus family 
of Rhadinovirus (Neipel, Albrecht, and Fleckenstein, 1997; Russo et al., 1996).  KSHV is 
etiologically associated with Kaposi’s sarcoma, primary effusion or body cavity-based 
lymphoma and multicentric Castleman’s disease (Antman and Chang, 2000; Ganem, 1998; 
Schulz, Sheldon, and Greensill, 2002).  In 1996, the KSHV genome derived from the BC-1 cell 
line was fully sequenced (Moore et al., 1996).  
KSHV encodes numerous glycoproteins during its lifecycle.  Many of these viral 
glycoproteins are crucial for virus entry and cell-to-cell spread (Knipe and and Straus, 2001).   
Glycoprotein B (gB) is conserved among all herpesvirus and it is thought to directly function in 
virion attachment, the fusion of viral envelope with cellular membranes and virus-induced cell 
fusion during virus entry into permissive cells (Cai, Gu, and Person, 1988; Cranage et al., 1986; 
Pereira, 1994).  Virus-induced cell fusion further allows for the spread of herpesvirus to 
neighboring cells (Baghian et al., 1993; Foster, Melancon, and Kousoulas, 2001).  KSHV gB is a 
structural component of the virion and is thought to mediate virus attachment to cell integrins on 
cell surfaces via a gB RGD amino acid motif.  One of the striking features of KSHV gB is that 
carboxyl terminal mutations can enhance virus-induced cell fusion (Baghian et al., 1993; Foster, 
Melancon, and Kousoulas, 2001; Pertel, 2002).  Also, KSHV gB is involved in virion egress in 
293T cells, since a gB-null virus was unable to egress from 293T cells, while complementation 
by exogenous gB restored virion egress (Krishnan et al., 2005).  These observations suggest that 
KSHV gB is important for both virion egress and infectivity.  
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Mutagenesis of viral genomes has been extensively used to assess the structure and 
function of individual viral proteins.  However, in the case of KSHV, recombinant viruses that 
carry deletions and other mutations are very difficult to construct largely due to difficulties 
associated with recovering substantial amounts of infectious virions after mutagenesis and 
transfection of viral DNA into susceptible cells. .   
The RNA interference (RNAi) pathway is active in mammals and RNAi has emerged as a 
highly efficient and powerful tool for investigating mammalian gene function.  Compared to 
knockout genetics, RNAi-based silencing is rapid, cost effective, and can be easily adapted to 
study homologous gene function in a wide variety of organisms.  RNAi depends on the 
formation of double-strand RNA (dsRNA), which has its antisense strand complementary to the 
transcript of a targeted gene.  The dsRNA silences the targeted gene by either inducing a 
sequence-specific degradation of complementary mRNA, or by inhibiting  translation (Mittal, 
2004).  Two distinct steps are involved (Hutvagner and Zamore, 2002b; McManus and Sharp, 
2002).  First, the enzyme Dicer cleaves long dsRNA into short interfering RNA (siRNA) 
molecules of 21-23 bp in length.  Second, a multicomponent RNA-induced silencing complex 
(RISC) uses siRNA to guide the sequence-specific cleavage of the RNA transcripts of the target 
gene.  Gene silencing by this mechanism has been accomplished by transfection of chemically 
synthesized siRNA into host cells, by-passing the “dicing” step, to silence or knockdown gene 
expression (McManus and Sharp, 2002).  Chemically synthesized 21-22 nucleotides (nt) siRNAs 
were shown to degrade mRNA via the RNAi mechanism evading the interferon response 
(Elbashir, Lendeckel, and Tuschl, 2001). 
Effective gene silencing primarily depends on three factors: target sequence selection, 
optimal delivery of siRNA to cells and persistence of siRNA expression.  Several recently 
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developed vector-based systems that contain stem-loop construct hairpin RNAs are able to 
induce intracellular generation of siRNA-like species (Brummelkamp, Bernards, and Agami, 
2002; McCaffrey et al., 2002; Paddison, Caudy, and Hannon, 2002; Paul et al., 2002; Sui et al., 
2002; Xia et al., 2002; Yu, DeRuiter, and Turner, 2002).  Dicer cleavage of hairpin RNA can 
generate small dsRNAs that silence expression of target genes whose transcripts are 
complementary to one of the two strands of the hairpin RNA (Hutvagner and Zamore, 2002b).  
However, most vector-based hairpin expression systems can only transiently inhibit gene 
expression.  Until recently, long-term knockdown of specific genes was achieved using retroviral 
vector constructs that express hairpin RNAs in cell cultures (Barton and Medzhitov, 2002; 
Brummelkamp, Bernards, and Agami, 2002; Devroe and Silver, 2002; Paddison and Hannon, 
2002).  The system for retrovirus delivery of RNAi-based gene silencing can also  be adapted to 
use in lentiviral systems (Stewart et al., 2003b) . 
Lentiviruses have the unique ability among retroviruses of being able to infect non-
dividing cells and expand the usefulness of the RNAi-based gene silencing system (Gropp and 
Reubinoff, 2007; Harper and Gonzalez-Alegre, 2008; Klinghoffer et al., 2008; Ren et al., 2007; 
Sumimoto and Kawakami, 2007).  As the particles are often pseudotyped with the envelope of 
the vesicular stomatitis virus (VSV), the vector can serve to introduce genes into a broad range 
of tissues and can be used in vivo.  Furthermore, it has been demonstrated to be an excellent in 
vivo expression system achieving gene expression for several months without detectable 
pathology.  
RNAi-mediated inhibition of KSHV gene expression has been previously utilized to 
ascertain the function of specific viral genes.  siRNA-mediated silencing of KSHV K13 
expression in PEL cell lines substantially inhibited NF-κB production and apoptosis (Godfrey et 
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al., 2005; Guasparri, Keller, and Cesarman, 2004).  Recently, we utilized siRNA to conditionally 
knockdown the expression of KSHV glycoprotein B in 293T and BCBL-1 cells. KSHV gB was 
then rescued by codon-optimized gB DNA, which could not be inhibited by the siRNA due to its 
altered sequence.  To achieve a stable and efficient siRNA-mediated knockdown of gB, we have 
used a lentivirus-based expression system.  The overall goal of this line of experimentation is to 
develop a durable lentiviral–RNAi based system that can effectively and permanently inhibit 
KSHV gB expression in BCBL-1 cells at much higher levels that the ones achieved with 
transient expression of siRNAs.  BCBL-1 cells incapable of expressing gB can then be used to 
delineate the functional domains of KSHV gB involved in virion egress, infectivity and 
tumorigenicity, by supplying in trans modified gBs that are not subject to siRNA inhibition.  
MATERIALS AD METHODS 
Cloning and Preparation of Lentiviral Vectors 
The construction of recombinant lentivirus expressing anti-gB siRNAs was accomplished by 
using the plenti6/V5-D-TOPO cloning system (Invitrogen).  The pLenti6/V5-D-TOPO vector is 
designed for use with the ViraPower Lentiviral Expression System (Invitrogen).  siRNAs were 
designed targeting the 5’ region of KSHV gB expression sequence using the AMBION’s online 
siRNA target finder.  The siRNA 18 was located from the nucleotide 403 after the ATG codon, 
while siRNA22 located starting at 484 bases from the ATG codon.  Two siRNAs were generated 
as follows: siRNA 18 sense strand (5'-CACCCAAGTATGAACTCCCGAGATTCAAGAGAT 
CTCGGGAGTTCATACTTGTT-3') and anti-sense strand (5'-AACAAGTATGAACTCCCAG 
ATCTCTTGAATCTCGGGAGTTCATACTTG-3'); siRNA22 sense strand (5'-CACCGGTAA 
ATGTCAACGGGGTATTCAAGAGATACCCCGTTGACATTTACCTT-3') and anti-sense 
strand (5'-AAGGTAAATGTCAACGGGGTATCTCTTGAATACCCCGTTGACATTTACC-3'). 
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The siRNAs contained the sequence CACC at the 5’ ends of sense strands respectively for 
cloning purposes.  The siRNA 18 and siRNA 22 were denatured at 94 ºC for 5 minutes and 
cooled down slowly to room temperature to allow annealing of the two strands.  To produce 
lentiviral-siRNA expression clones, each annealed siRNA was TOPO-cloned into the 
pLenti6/V5-D-TOPO vector.  After TOPO cloning, One Shot Stbl3 chemically competent E. coli 
cells (Invitrogen) were transformed with DNA according to the manufacturer’s protocol and 
spread on LB agar plate containing 100 µg/ml ampicillin.  All constructs containing siRNAs 
were verified by BamHI/XhoI restriction enzymes digestion and sequenced to confirm their 
structure.   
Transfection 
The 293FT lentiviral packaging cell line was obtained from the ViraPower Lentiviral Expression 
Kit (Invitrogen).  293FT cell lines were cultured according to the manufacturer’s instructions.  
293FT cells were cultured in a six-well plate in 2ml of antibiotic-free DMEM/10% heat 
inactivated fetal bovine serum (FBS) medium.  Transfection was done until 293FT cells 
replicated to 80% confluence.  293FT cells were transfected with 1µg pLenti6/V5-D-TOPO 
vector and 3µg ViraPower packaging mix (Invitrogen) using 12µl LipofectAMINE 2000 
(Invitrogen) in 1ml OptiMEM transfection medium without serum (Invitrogen).  After overnight, 
media was removed and 3ml of antibiotic-free DMEM/10% FBS was supplied.  The 293FT cells 
were allowed to produce lentivirus for 72h post-infection.  Media containing live lentivirus was 
harvested and spun-down to remove cell debris before storage at -80 °C.  
Infectivity of Lentiviruses in BCBL-1 Cells 
BCBL-1 cells were allowed to grow to 60% confluence in T75 flasks.  Cells were spun-down 
and suspended in 0.5ml cell culture media per well of 12-well plate.  Cells were infected with 
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0.5ml lentivirus and polybrene (hexadimethrine bromide) at a final concentration of 8µg/ml.  
Cells were infected for 12h before replacement of another 1 ml cell culture media.  BCBL-1 cells 
were incubated for 72h before the aspiration of cell culture media.  To select stable cell line, 
blasticidin (Invitrogen) was used at a final concentration of 5-7.5µg/ml.  Cells were cultured in 
the presence of blasticidin for 20 day to ensure stable cell line selection.  
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